

## PRODUCT MONOGRAPH

### **Pr BORTEZOMIB FOR INJECTION**

Bortezomib (as mannitol boronic ester)  
Sterile Powder for Injection

3.5 mg bortezomib/vial

Antineoplastic Agent

Teva Canada Limited  
30 Novopharm Court,  
Toronto, Ontario  
M1B 2K9

Date of Revision: May 26, 2016

Control No. 194967

## **Table of Contents**

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE .....	3
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	12
DRUG INTERACTIONS .....	30
DOSAGE AND ADMINISTRATION .....	31
OVERDOSAGE .....	39
ACTION AND CLINICAL PHARMACOLOGY .....	40
STORAGE AND STABILITY .....	41
SPECIAL HANDLING INSTRUCTIONS .....	42
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	42
 <b>PART II: SCIENTIFIC INFORMATION .....</b>	 <b>43</b>
PHARMACEUTICAL INFORMATION.....	43
CLINICAL TRIALS .....	44
DETAILED PHARMACOLOGY .....	67
TOXICOLOGY .....	71
REFERENCES .....	76
 <b>PART III: CONSUMER INFORMATION.....</b>	 <b>78</b>

## **Pr**BORTEZOMIB FOR INJECTION

Bortezomib (as mannitol boronic ester)  
Sterile Powder for Injection

3.5 mg bortezomib/vial

Antineoplastic Agent

### **PART I: HEALTH PROFESSIONAL INFORMATION**

#### **SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Pharmaceutical Form/Strength</b>	<b>Clinically Relevant Nonmedical Ingredients</b>
Intravenous or subcutaneous	sterile lyophilized powder for injection / 3.5 mg	None

#### **INDICATIONS AND CLINICAL USE**

BORTEZOMIB FOR INJECTION (bortezomib) is indicated as follows:

- as part of combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation.
- as part of a medically recognized combination therapy for induction treatment of patients with previously untreated multiple myeloma who are suitable for stem cell transplantation (studies were conducted with intravenous administration of bortezomib).
- for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for stem cell transplantation. Bortezomib administered subcutaneously was studied in this patient population where it was shown to be non-inferior to the intravenous administration (defined as retaining at least 60% of the intravenous administration effect) (see **Product Monograph PART II, CLINICAL TRIALS**).
- as part of combination therapy for the treatment of patients with previously untreated mantle cell lymphoma who are unsuitable for stem cell transplantation.
- for the treatment of patients with mantle cell lymphoma who have relapsed or were refractory to at least 1 prior therapy.

#### **Geriatrics (> 65 years of age):**

No overall differences in safety or effectiveness of bortezomib were observed between younger patients and patients  $\geq 65$  years of age. Greater sensitivity of some older individuals cannot be ruled out (see **ADVERSE REACTIONS, ACTION AND**

## CLINICAL PHARMACOLOGY, and *Product Monograph* PART II, CLINICAL TRIALS).

### **Pediatrics and Adolescents (< 18 years of age):**

The safety and effectiveness of bortezomib in children and adolescents have not been established.

## **CONTRAINDICATIONS**

BORTEZOMIB FOR INJECTION is contraindicated in patients with hypersensitivity to bortezomib, boron or any of the excipients.

BORTEZOMIB FOR INJECTION is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of bortezomib.

## **WARNINGS AND PRECAUTIONS**

### **Serious Warnings and Precautions**

- BORTEZOMIB FOR INJECTION must be administered under the supervision of a physician qualified in the use of antineoplastic agents.
- Twice the recommended dose has been fatal (see **WARNINGS AND PRECAUTIONS, General**)
- Hypotension and other serious cardiac disorders (see **WARNINGS AND PRECAUTIONS, Cardiovascular**, and **ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions and Post-Market Adverse Drug Reactions**)
- Hemorrhage (gastrointestinal and intracerebral) (see **WARNINGS AND PRECAUTIONS, Hematologic** and **ADVERSE REACTIONS, Post-Market Adverse Drug Reactions**)
- Severe motor neuropathy, including fatalities (see **WARNINGS AND PRECAUTIONS, Neurologic**)
- Acute diffuse infiltrative pulmonary disease (see **WARNINGS AND PRECAUTIONS, Respiratory**)

### **General**

#### **Dose Preparation:**

Bortezomib has a narrow therapeutic window and has shown high acute toxicity in all animal species evaluated. Fatalities have been reported after accidental administration of at least twice the recommended dose in patients (see **OVERDOSAGE**). Careful attention is required to ensure the recommended dose is not exceeded.

The recommended starting dose of BORTEZOMIB FOR INJECTION is 1.3 mg/m<sup>2</sup>. BORTEZOMIB FOR INJECTION may be administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL (see **DOSAGE AND ADMINISTRATION**). When administered intravenously, BORTEZOMIB FOR INJECTION is administered as a 3 to 5 second bolus intravenous injection.

BORTEZOMIB FOR INJECTION is for intravenous or subcutaneous use only.  
BORTEZOMIB FOR INJECTION should not be administered by any other route.

**Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered.**

**Tumour Lysis Syndrome:**

Because BORTEZOMIB FOR INJECTION is a cytotoxic agent and can rapidly kill malignant plasma cells, the complications of tumour lysis syndrome may occur. The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

**Carcinogenesis and Mutagenesis**

Carcinogenicity studies have not been conducted. Bortezomib was clastogenic in mammalian cells in the *in vitro* chromosomal aberration assay. Bortezomib was not mutagenic in bacteria (Ames assay) and in the *in vivo* micronucleus assay in mice (see **Product Monograph PART II, TOXICOLOGY**).

**Cardiovascular**

**Hypotension**

Bortezomib treatment is commonly associated with orthostatic/postural hypotension which is not an acute reaction and is observed throughout treatment (see **ADVERSE REACTIONS**). In the Phase II and III relapsed multiple myeloma studies, the incidence of hypotension (postural, orthostatic, and hypotension NOS) was 11% and 12%, respectively. In the Phase II study, there was no prior history of orthostatic hypotension in these patients but half had pre-existing hypertension, one-third had evidence of peripheral neuropathy, and orthostatic hypotension was associated with syncope in some patients. In another Phase II study, there was evidence of autonomic nervous system abnormalities following bortezomib therapy. The mechanism is unknown although it may be due to bortezomib-induced autonomic neuropathy. Most cases required pharmacological treatment, including hydration and/or adjustment of antihypertensive medications. Administration of mineralocorticoids and/or sympathomimetics was infrequently required. Caution should be used when treating patients with a history of syncope, patients receiving medications known to be associated with hypotension, and patients who are dehydrated. Patients should be instructed to seek medical advice if they experience symptoms of dizziness, light-headedness or fainting spells.

**Congestive Heart Failure**

Acute development or exacerbation of congestive heart failure and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. Patients with risk factors for or existing heart disease should be closely monitored.

### **QT Prolongation**

There have been isolated cases of QT-interval prolongation in clinical studies; causality has not been established.

### **Pericarditis**

Events of pericarditis (<1%) have been reported in clinical trials and during post-marketing use of bortezomib. New or worsening cases of pericarditis should be investigated promptly.

In the Phase III relapsed multiple myeloma study of intravenous bortezomib versus dexamethasone, the incidence of any treatment-emergent cardiac disorder was 15% and 13% in the bortezomib and dexamethasone groups, respectively. The incidence of heart failure events (acute pulmonary edema, cardiac failure, congestive cardiac failure, cardiogenic shock, pulmonary edema) was similar in the bortezomib and dexamethasone groups, 5% and 4%, respectively.

### **Gastrointestinal**

Gastrointestinal events, including nausea, diarrhea, constipation, and vomiting occur frequently during bortezomib treatment (see **ADVERSE REACTIONS**). Events usually occur earlier in treatment (Cycles 1 and 2), and may persist for several cycles, sometimes requiring administration of antiemetics and antidiarrheals. Fluid and electrolyte replacement should be administered if the patient becomes dehydrated. Cases of intestinal obstruction, including ileus, have been reported and patients who experience constipation should be closely monitored (see **WARNINGS AND PRECAUTIONS**, Neurologic, Autonomic Neuropathy).

### **Hematologic**

BORTEZOMIB FOR INJECTION is associated with thrombocytopenia and neutropenia (see **ADVERSE REACTIONS**). A cyclical pattern of platelet and neutrophil decrease and recovery has remained consistent in the studies of multiple myeloma and mantle cell lymphoma, with no evidence of cumulative thrombocytopenia or neutropenia in any of the regimens studied. Of the bortezomib dosing days in each cycle of bortezomib treatment, platelets were lowest on Day 11, and neutrophils were generally lowest on Days 8-11, of each cycle. Platelets and neutrophils typically recovered to baseline by the next cycle.

Platelet counts should be monitored prior to each dose of BORTEZOMIB FOR INJECTION. Complete blood counts (CBC) with differential should be frequently monitored throughout treatment with BORTEZOMIB FOR INJECTION. BORTEZOMIB FOR INJECTION therapy should be held when the platelet count is <25,000/uL or <30,000/ uL when used in combination with melphalan and prednisone (see **DOSAGE AND ADMINISTRATION**). There have been reports of gastrointestinal and intracerebral hemorrhage in association with bortezomib. Transfusion and supportive care should be considered.

In the single-agent multiple myeloma study of bortezomib vs dexamethasone, the mean platelet count nadir measured was approximately 40% of baseline. The severity of thrombocytopenia related to pre-treatment platelet count is shown in Table 1.1. The incidence of significant bleeding events ( $\geq$  Grade 3) was similar on both the bortezomib (4%) and dexamethasone (5%) arms.

**Table 1.1: The Severity of Thrombocytopenia Related to Pre-Treatment Platelet Count in the Phase III Relapsed Multiple Myeloma Study of Intravenous Bortezomib versus Dexamethasone**

Pre-treatment Platelet Count <sup>†</sup>	Number of Patients (N=331) <sup>‡</sup>	Number (%) of Patients with Platelet Count $<10 \times 10^9/L$	Number (%) of Patients with Platelet Count $10 \times 10^9 - 25 \times 10^9/L$
$\geq 75 \times 10^9/L$	309	8 (3%)	36 (12%)
$\geq 50 \times 10^9/L - < 75 \times 10^9/L$	14	2 (14%)	11 (79%)
$\geq 10 \times 10^9/L - < 50 \times 10^9/L$	7	1 (14%)	5 (71%)

<sup>†</sup> A baseline platelet count of  $50 \times 10^9/L$  was required for study eligibility.

<sup>‡</sup> Data were missing at baseline for 1 patient.

In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (VcR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia adverse reactions ( $\geq$  Grade 4) was 32% versus 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm. The incidence of bleeding adverse reactions ( $\geq$  Grade 3) associated with low platelet counts (Grade 3 or higher) within the same or prior cycle, up to the end of the bleeding event was 1% (3 patients) in the VcR-CAP treatment arm and  $<1\%$  (1 subject) in the R-CHOP treatment arm.

There were no deaths due to bleeding events in either arm. There were no CNS bleeding events in the VcR-CAP arm; there was 1 bleeding event in the R-CHOP arm. Platelet transfusions were given to 23% of the patients in the VcR-CAP arm and 3% of the patients in the R-CHOP arm.

The incidence of neutropenia adverse reactions ( $\geq$  Grade 4) was 70% in the VcR-CAP arm and was 52% in the R-CHOP arm. The incidence of febrile neutropenia ( $\geq$  Grade 4) was 5% in the VcR-CAP arm and was 6% in the R-CHOP arm. Colony-stimulating factor support was provided at a rate of 78% in the VcR-CAP arm and 61% in the R-CHOP arm.

### **Hepatic/Biliary**

Bortezomib is metabolized by liver enzymes. Bortezomib exposure is increased in patients with moderate or severe hepatic impairment; these patients should be treated with BORTEZOMIB FOR INJECTION at reduced starting doses and closely monitored for toxicities (see **DOSAGE AND ADMINISTRATION**).

Rare cases of acute liver failure have been reported in bortezomib-treated patients receiving multiple concomitant medications and with serious underlying medical conditions. Other reported hepatic events include asymptomatic increases in liver enzymes, hyperbilirubinemia, and hepatitis. Such changes may be reversible upon discontinuation of BORTEZOMIB FOR INJECTION. There is limited re-challenge information in these patients.

## **Neurologic**

### **Peripheral Neuropathy**

Treatment with bortezomib is commonly associated with peripheral neuropathy that is predominantly sensory. However, cases of severe motor neuropathy with or without sensory peripheral neuropathy have been reported, including those with fatal outcomes. Rare cases of Guillain-Barré syndrome without established causal relationship to bortezomib and aspiration pneumonia in association with motor neuropathy have also been reported.

In clinical trials in relapsed multiple myeloma, of the patients who experienced treatment-emergent neuropathy, 70% had previously been treated with neurotoxic agents and 80% had signs or symptoms of peripheral neuropathy at baseline. Worsening of existing neuropathy is dose related and cumulative. Patients with pre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy (hyperesthesia, hypoesthesia, paresthesia, neuropathic pain or weakness) may experience worsening during treatment with BORTEZOMIB FOR INJECTION and it is recommended that all patients should be monitored for symptoms of neuropathy.

Complete resolution of peripheral neuropathy to baseline has been documented in 14% of patients with severe symptoms in the Phase II studies in relapsed multiple myeloma, with limited follow-up data available. In the Phase III relapsed multiple myeloma study, following dose adjustments, improvement in or resolution of peripheral neuropathy was reported in 51% of patients with  $\geq$  Grade 2 peripheral neuropathy, and the median time to improvement or resolution was 107 days. Bortezomib was discontinued because of peripheral neuropathy in 8% of patients in the Phase III study, and was the most common adverse event leading to treatment discontinuation. Improvement in or resolution of peripheral neuropathy was reported in 71% of patients who discontinued due to peripheral neuropathy or who had  $\geq$  Grade 3 peripheral neuropathy in the Phase II multiple myeloma studies (see **ADVERSE REACTIONS**). The mechanism underlying bortezomib-induced peripheral neuropathy is not known and the complete time-course of this toxicity has not been fully characterized. Full reversibility has not been demonstrated in preclinical studies (see **Product Monograph PART II, TOXICOLOGY**).

In the Phase III relapsed multiple myeloma study comparing bortezomib administered intravenously vs. subcutaneously, the incidence of Grade  $\geq 2$  peripheral neuropathy events was 24% for subcutaneous and 41% for intravenous. Grade  $\geq 3$  peripheral neuropathy occurred in 6% of subjects in the subcutaneous treatment group, compared



with 16% in the intravenous treatment group. Therefore, patients with pre-existing peripheral neuropathy or at high risk of peripheral neuropathy may benefit from starting BORTEZOMIB FOR INJECTION subcutaneously. Starting BORTEZOMIB FOR INJECTION subcutaneously may be considered for patients with pre-existing or at risk of peripheral neuropathy. Patients with pre-existing severe neuropathy should be treated with BORTEZOMIB FOR INJECTION only after careful risk-benefit assessment.

Patients experiencing new or worsening peripheral neuropathy may require a change in the dose, schedule or cessation of BORTEZOMIB FOR INJECTION therapy (see **DOSAGE AND ADMINISTRATION**).

### **Autonomic Neuropathy**

Autonomic neuropathy may contribute to some adverse reactions, such as postural hypotension, diarrhea, constipation with ileus and pyrexia. Severe autonomic neuropathy resulting in treatment interruption or discontinuation has been reported (see **DOSAGE AND ADMINISTRATION**).

### **Seizures**

Seizures are uncommonly reported in patients without previous history of seizures. Caution should be exercised when treating patients with any risk factors.

### **Posterior reversible encephalopathy syndrome:**

There have been rare reports of posterior reversible encephalopathy syndrome (PRES) (formerly RPLS) in patients receiving bortezomib. PRES is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. Brain imaging, preferably MRI (Magnetic Resonance Imaging), is used to confirm the diagnosis. In patients developing PRES, discontinue BORTEZOMIB FOR INJECTION. The safety of reinitiating bortezomib therapy in patients previously experiencing PRES is not known.

### **Progressive Multifocal Leukoencephalopathy (PML):**

Cases of John Cunningham (JC) virus infection of unknown causality, resulting in PML and death, have been reported in patients treated with bortezomib. Very rare post-marketing cases of PML have been reported in patients treated with bortezomib in combination with, or following other therapies. Signs and symptoms of PML include new onset or worsening neurological signs or symptoms such as confusion or problems thinking, loss of balance, blurred vision or loss of vision, decreased strength or weakness in an arm or leg or change in the way of walking or talking. If such signs or symptoms are observed, PML should be considered in the differential diagnosis, and further evaluation is recommended, including consideration of a neurologist consultation. Discontinue BORTEZOMIB FOR INJECTION if PML is diagnosed.

## **Renal**

Hypercalcemia and renal failure are complications of multiple myeloma most often associated with high tumour burden. Supportive treatments for these complications include bisphosphonates (for hypercalcemia and myeloma bone disease), hydration and other measures depending on the patient's status and the type and severity of the complications (see ***Product Monograph PART II, CLINICAL TRIALS***).

Bortezomib has not been formally studied in patients with impaired renal function. Limited clinical information is available on the use of bortezomib in patients with varying degrees of impaired renal function (see ***Product Monograph PART II, CLINICAL TRIALS***). No clinical information is available on the use of bortezomib in patients on hemodialysis. Patients with renal impairment, especially if creatinine clearance is  $\leq 30$  mL/min, should be closely monitored for toxicities when treated with BORTEZOMIB FOR INJECTION (see **ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions**).

## **Respiratory**

There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome (ARDS) in patients receiving bortezomib. Some of these events have been fatal. A pre-treatment chest radiography should be done to determine if any additional diagnostic measures are necessary and to serve as a baseline for potential post-treatment pulmonary changes.

In the event of new or worsening pulmonary symptoms (e.g., cough, dyspnea), a prompt diagnostic evaluation should be performed and patients treated appropriately. The benefit/risk ratio should be considered prior to continuing BORTEZOMIB FOR INJECTION therapy.

In a clinical trial, two patients given high-dose cytarabine (2 g/m<sup>2</sup> per day) by continuous infusion over 24 hours with daunorubicin and bortezomib for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. Therefore, this specific regimen is not recommended.

## **Sexual Function/Reproduction**

Fertility studies with bortezomib have not been performed. Degenerative effects in ovaries and testes in the general toxicity studies suggest a potential effect on male and female fertility (see ***Product Monograph PART II, TOXICOLOGY***).

## **Amyloidosis**

Limited clinical information is available on the use of bortezomib in patients with previously treated light-chain (AL) amyloidosis.

There is no information for bortezomib in patients with concurrent multiple myeloma and AL amyloidosis. Therefore, when considering the treatment of patients with multiple myeloma who also have AL amyloidosis, potential risk of complications due to organ involvement must be taken into account. Close monitoring of organ function (cardiac, renal, hepatic and nervous systems) should be performed regularly to guide dose adjustments and duration of therapy.

### **Special Populations**

#### **Pregnant Women:**

Women of child-bearing potential should avoid becoming pregnant while being treated with BORTEZOMIB FOR INJECTION. Males and females of child-bearing capacity should use effective contraceptive measures during treatment and for 3 months following treatment.

Bortezomib was not teratogenic in rats and rabbits at the highest dose tested (0.45 and 0.55 mg/m<sup>2</sup>, respectively) but caused post-implantation loss in rabbits (see ***Product Monograph PART II, TOXICOLOGY***).

No placental transfer studies have been conducted with bortezomib. There are no adequate and well-controlled studies in pregnant women. If BORTEZOMIB FOR INJECTION is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be aware of the potential hazard to the fetus.

#### **Nursing Women:**

It is not known whether bortezomib is excreted in milk. Because many drugs are excreted in milk and because of the potential for serious adverse reactions from BORTEZOMIB FOR INJECTION in nursing infants, women should be advised against breast-feeding while being treated with BORTEZOMIB FOR INJECTION.

#### **Pediatrics (< 18 years of age):**

The safety and effectiveness of BORTEZOMIB FOR INJECTION in children and adolescents have not been established.

### **Monitoring and Laboratory Tests**

Platelet counts should be monitored prior to each dose of BORTEZOMIB FOR INJECTION. Complete blood counts (CBC) with differential should be frequently monitored throughout treatment with BORTEZOMIB FOR INJECTION.

Chest radiography should be done prior to initiating BORTEZOMIB FOR INJECTION therapy (see **WARNINGS AND PRECAUTIONS, Respiratory**).

## ADVERSE REACTIONS

### **Adverse Drug Reaction Overview**

The most commonly reported adverse reactions during treatment with bortezomib are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.

Serious adverse reactions reported during treatment with bortezomib include cardiac failure, tumour lysis syndrome, pulmonary hypertension, posterior reversible encephalopathy syndrome, acute diffuse infiltrative pulmonary disorders and rarely autonomic neuropathy. These were uncommonly reported.

### ***Multiple Myeloma and Mantle Cell Lymphoma***

#### **Herpes Zoster Virus Reactivation:**

The administration of bortezomib has been associated with herpes zoster reactivation. In the randomized Phase III study in relapsed multiple myeloma, the incidence of herpes zoster occurring on treatment with bortezomib was 13% (42/331) versus 5% (15/332) in the high-dose dexamethasone group. In the randomized study in patients with previously untreated multiple myeloma, the overall incidence of herpes zoster reactivation was more common in subjects treated with intravenous bortezomib, melphalan and prednisone (VMP) than in the control group treated with melphalan and prednisone (14% vs. 4%, respectively). In this study, antiviral prophylaxis was administered to 26% (90/340) of patients in the VMP treatment group. In this treatment group, herpes zoster virus reactivation was less common in subjects receiving prophylactic antiviral therapy (3% [3/90]) than in subjects who did not receive prophylactic antiviral therapy (17% [43/250]). In patients with previously untreated MCL, the incidence of herpes zoster infection was 6.7% in the VcR-CAP arm and 1.2% in the R-CHOP arm. In the post-market setting, cases of herpes meningoencephalitis and ophthalmic herpes have been reported.

### **Clinical Trial Adverse Drug Reactions**

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

### ***Multiple Myeloma***

#### **Randomized Open-Label Combination Phase III Clinical Study in Patients with Previously Untreated Multiple Myeloma (Front-Line Therapy, Intravenous Bortezomib)**

In the bortezomib, melphalan, prednisone (VMP) and melphalan, prednisone (MP) treatment groups, respectively, 99% and 97% of subjects experienced at least 1 treatment-

emergent adverse event. Seventy-eight percent of subjects in the VMP treatment group had Blood and Lymphatic System Disorders considered related to study drug, compared with 70% in the MP treatment group. The most commonly reported adverse events thrombocytopenia (52% vs. 47%), neutropenia (49% vs. 46%), and leukopenia (33% vs. 30%) were comparable between the 2 treatment groups (VMP vs. MP). The incidence of lymphopenia was higher in the VMP group (24% vs. 17%). However, anemia was observed in only 43% of subjects in the VMP group compared to 55% in the MP group. The Gastrointestinal Disorders SOC Grades 3 and  $\geq 4$  were reported more frequently in the VMP treatment group as compared to the MP treatment group (nausea: 48% vs. 28%; diarrhea: 46% vs. 17%; constipation: 37% vs. 16%; vomiting: 33% vs. 16%). As well, the incidence of Nervous System Disorders was higher in the VMP group (VMP vs. MP): peripheral neuropathy (47% vs. 5%), neuralgia (36% vs. 1%), and paraesthesia (13% vs. 4%). The incidence of termination of all study treatment because of adverse events was similar for the VMP and MP treatment groups (15% vs. 14%, respectively).

A total of 155 (46%) patients from the VMP treatment group experienced a serious adverse event (SAE) during the study compared with 121 (36%) patients from the MP treatment group. The most frequently reported serious adverse events in both treatment groups were in the Infections and Infestation SOC (VMP: 17%; MP: 15%), with pneumonia being the predominant serious adverse event in both treatment groups (VMP: 11%, MP: 7%). The incidence of serious adverse events belonging to the Nervous System Disorders was 5% in the VMP treatment group and 2% in the MP treatment group.

Drug-related adverse events that led to death during the study occurred in 2% of subjects in both treatment groups (6 subjects in the VMP treatment group and 8 subjects in the MP treatment group). The most frequent drug-related adverse events leading to death were of infectious origin: drug-related pneumonia/bronchopneumonia led to death in 3 subjects in the VMP treatment group and 4 subjects in the MP treatment group and drug-related sepsis led to death in 1 subject in the VMP treatment group and 3 subjects in the MP treatment group.

Table 1.2 describes safety data from 340 patients with previously untreated multiple myeloma who received intravenous bortezomib ( $1.3 \text{ mg/m}^2$ ) in combination with melphalan ( $9 \text{ mg/m}^2$ ) and prednisone ( $60 \text{ mg/m}^2$ ) in a prospective Phase 3 study. Overall, the safety profile of bortezomib in combination with melphalan/prednisone is consistent with the known safety profiles of both bortezomib and melphalan/prednisone.

**Table 1.2: Most Commonly Reported Adverse Events ( $\geq 10\%$  in Intravenous Bortezomib, Melphalan and Prednisone arm) with Grades 3 and  $\geq 4$  Intensity in the Previously Untreated Multiple Myeloma Study**

MedDRA System Organ Class Preferred Term	Bortezomib, Melphalan and Prednisone (N=340)			Melphalan and Prednisone (N=337)		
	Total	Toxicity Grade, n (%)		Total	Toxicity Grade, n (%)	
	n (%)	3	$\geq 4$	n (%)	3	$\geq 4$

MedDRA System Organ Class Preferred Term	Bortezomib, Melphalan and Prednisone (N=340)			Melphalan and Prednisone (N=337)		
	Total	Toxicity Grade, n (%)		Total	Toxicity Grade, n (%)	
	n (%)	3	≥ 4	n (%)	3	≥ 4
<b>Blood and Lymphatic System Disorders</b>						
Thrombocytopenia	178 (52)	68 (20)	59 (17)	159 (47)	55 (16)	47 (14)
Neutropenia	165 (49)	102 (30)	35 (10)	155 (46)	79 (23)	49 (15)
Anemia	147 (43)	53 (16)	9 (3)	187 (55)	66 (20)	26 (8)
Leukopenia	113 (33)	67 (20)	10 (3)	100 (30)	55 (16)	13 (4)
Lymphopenia	83 (24)	49 (14)	18 (5)	58 (17)	30 (9)	7 (2)
<b>Gastrointestinal Disorders</b>						
Nausea	164 (48)	14 (4)	0	94 (28)	1 (<1)	0
Diarrhea	157 (46)	23 (7)	2 (1)	58 (17)	2 (1)	0
Constipation	125 (37)	2 (1)	0	54 (16)	0	0
Vomiting	112 (33)	14 (4)	0	55 (16)	2 (1)	0
Abdominal Pain	49 (14)	7 (2)	0	22 (7)	1 (<1)	0
Abdominal Pain Upper	40 (12)	1 (<1)	0	29 (9)	0	0
Dyspepsia	39 (11)	0	0	23 (7)	0	0
<b>Nervous System Disorders</b>						
Peripheral Neuropathy	159 (47)	43 (13)	2 (1)	18 (5)	0	0
Neuralgia	121 (36)	28 (8)	2 (1)	5 (1)	1 (<1)	0
Dizziness	56 (16)	7 (2)	0	37 (11)	1 (<1)	0
Headache	49 (14)	2 (1)	0	35 (10)	4 (1)	0
Paresthesia	45 (13)	6 (2)	0	15 (4)	0	0
<b>General Disorders and Administration Site Conditions</b>						
Pyrexia	99 (29)	8 (2)	2 (1)	64 (19)	6 (2)	2 (1)
Fatigue	98 (29)	23 (7)	2 (1)	86 (26)	7 (2)	0
Asthenia	73 (21)	20 (6)	1 (<1)	60 (18)	9 (3)	0
Edema Peripheral	68 (20)	2 (1)	0	34 (10)	0	0
<b>Infections and Infestations</b>						
Pneumonia	56 (16)	16 (5)	13 (4)	36 (11)	13 (4)	9 (3)
Herpes Zoster	45 (13)	11 (3)	0	14 (4)	6 (2)	0
Bronchitis	44 (13)	4 (1)	0	27 (8)	4 (1)	0
Nasopharyngitis	39 (11)	1 (<1)	0	27 (8)	0	0
<b>Musculoskeletal and Connective Tissue Disorders</b>						
Back Pain	58 (17)	9 (3)	1 (<1)	62 (18)	11 (3)	1 (<1)
Pain In Extremity	47 (14)	8 (2)	0	32 (9)	3 (1)	1 (<1)
Bone Pain	37 (11)	7 (2)	1 (<1)	35 (10)	7 (2)	0
Arthralgia	36 (11)	4 (1)	0	50 (15)	2 (1)	1 (<1)
<b>Metabolism and Nutrition Disorders</b>						
Anorexia	77 (23)	9 (3)	1 (<1)	34 (10)	4 (1)	0
Hypokalemia	44 (13)	19 (6)	3 (1)	25 (7)	8 (2)	2 (1)
<b>Skin and Subcutaneous Tissue Disorders</b>						
Rash	66 (19)	2 (1)	0	24 (7)	1 (<1)	0
Pruritus	35 (10)	3 (1)	0	18 (5)	0	0
<b>Respiratory, Thoracic and Mediastinal Disorders</b>						
Cough	71 (21)	0	0	45 (13)	2 (1)	0
Dyspnea	50 (15)	11 (3)	2 (1)	44 (13)	5 (1)	4 (1)
<b>Psychiatric Disorders</b>						
Insomnia	69 (20)	1 (<1)	0	43 (13)	0	0
<b>Vascular Disorders</b>						
Hypertension	45 (13)	8 (2)	1 (<1)	25 (7)	2 (1)	0
Hypotension	41 (12)	4 (1)	3 (1)	10 (3)	2 (1)	2 (1)

**Randomized Open-Label Phase III Clinical Studies of Intravenous Bortezomib-based Combination Induction Treatment in Patients with Previously Untreated Multiple Myeloma Suitable for Stem Cell Transplantation (pooled safety data from 3 studies)**

Safety data was collected from three randomized, open-label, Phase 3 studies (MMY-3003, IFM 2005-01, and MMY-3010) in which Bortezomib for Injection at a dose of 1.3 mg/m<sup>2</sup> was used as part of the induction treatment administered to patients with newly diagnosed multiple myeloma who were eligible for stem cell transplantation. Data from these studies were pooled, and the safety comparison of interest was the bortezomib-based induction regimen (i.e. bortezomib/doxorubicin/dexamethasone [VcAD], bortezomib /dexamethasone [VcD], and bortezomib/thalidomide/dexamethasone [VcTD] treatment groups) versus non-bortezomib-based induction regimen (i.e. vincristine/doxorubicin/dexamethasone [VAD] and thalidomide/dexamethasone [TD] treatment groups). The pooled safety population consisted of 1,555 subjects.

During induction, 94% and 96% of subjects in the non-bortezomib-based and bortezomib-based groups, respectively, experienced at least 1 treatment-emergent adverse event. Across both the non-bortezomib-based and bortezomib-based groups, very common (≥10%) treatment-emergent adverse events during the induction phase were constipation (non-Vc-based: 28%; Vc-based: 31%), anemia (non-Vc-based: 29%; Vc-based: 27%), nausea (non-Vc-based: 27%; Vc-based: 28%), thrombocytopenia (non-Vc-based: 22%; Vc-based: 31%), leukopenia (non-Vc-based: 27%; Vc-based: 25%), fatigue (non-Vc-based: 21%; Vc-based: 20%), hepatic function abnormal (non-Vc-based: 20%; Vc-based: 21%), and pyrexia (non-Vc-based: 20%; Vc-based: 20%). Peripheral neuropathy was reported more frequently in the Vc-based group (19%) as compared with the non-Vc based group (7%). Patients did not have any evidence of peripheral neuropathy at baseline.

Serious treatment-emergent adverse events were reported by 37% of subjects in the non-bortezomib-based group and 41% of subjects in the bortezomib-based group. Across both the non-bortezomib-based and bortezomib-based groups, the most frequently reported treatment-emergent serious adverse events during the Induction Phase were pneumonia (non-Vc-based: 6%; Vc-based: 5%), pyrexia (non-Vc-based: 5%; Vc-based: 5%), pulmonary embolism (non-Vc-based: 2%; Vc-based: 3%), deep vein thrombosis (non-Vc-based: 2%; Vc-based: 2%), vomiting (non-Vc-based: 1%; Vc-based: 2%), diarrhea (non-Vc-based: 1%; Vc-based: 2%), and peripheral sensory neuropathy (non-Vc-based: 0%; Vc-based: 3%). Diverticular perforation was also reported (non-Vc-based: 0.1%; Vc-based: 0.4%). Incidences of serious adverse events were comparable between the treatment groups.

Two percent of subjects in each treatment group had a treatment-emergent drug-related adverse event that resulted in death. The most frequently reported drug-related, Grade 3 or higher, and serious adverse events resulting in death were pneumonia, septic shock, sepsis and multi-organ failure. One case of sudden death considered related to bortezomib by the investigator was reported. One case of fatal viral myocarditis was

considered possibly related to study treatment (bortezomib/doxorubicin/dexamethasone) by the investigator. There were no notable differences between the treatment groups in the incidences of adverse events resulting in death.

Fifty-nine percent and 63% of subjects in the non-bortezomib-based and bortezomib – based groups, respectively, experienced at least 1 treatment-emergent adverse event with a toxicity Grade of 3 or higher; drug-related Grade 3 or higher treatment-emergent adverse events were reported by 45% and 51% of subjects, respectively.

Very common ( $\geq 10\%$ ) treatment-emergent adverse events from the pivotal IFM 2005-01 study are presented in Table 1.3. Very common ( $\geq 10\%$ ) treatment-emergent adverse events from the pooled studies are presented in Table 1.4.

**Table 1.3: Very Common Reported Adverse Events ( $\geq 10\%$  in Bortezomib-based arm) with Grade  $\geq 3$  Intensity in the Phase III Study of Bortezomib-based Combination Induction Treatment in Patients with Previously Untreated Multiple Myeloma Suitable for Stem Cell Transplantation (IFM-2005 Safety for Induction Analysis Set)**

MedDRA SOC Preferred term	Non Bortezomib-Based N = 239		Bortezomib-Based N = 239	
	Total n (%)	Grade $\geq 3$ n (%)	Total n (%)	Grade $\geq 3$ n (%)
<b>Gastrointestinal disorders</b>				
Constipation	61 (26)	1 (<1)	60 (25)	1 (<1)
Nausea	70 (29)	1 (<1)	50 (21)	4 (2)
Diarrhea	24 (10)	1 (<1)	30 (13)	4 (2)
<b>General disorders and administration site conditions</b>				
Asthenia	48 (20)	3 (1)	53 (22)	8 (3)
Pyrexia	56 (23)	6 (3)	32 (13)	2 (1)
Edema peripheral	19 (8)	1 (<1)	29 (12)	0
<b>Nervous system disorders</b>				
Paresthesia	36 (15)	2 (1)	47 (20)	5 (2)
Neuropathy peripheral	5 (2)	1 (<1)	29 (12)	8 (3)
<b>Musculoskeletal and connective tissue disorders</b>				
Back pain	27 (11)	5 (2)	35 (15)	5 (2)
<b>Blood and lymphatic system disorders</b>				
Anemia	54 (23)	21 (9)	46 (19)	12 (5)
Thrombocytopenia	11 (5)	3 (1)	27 (11)	7 (3)
<b>Psychiatric disorders</b>				
Insomnia	24 (10)	1 (<1)	31 (13)	1 (<1)



**Table 1.4: Very Common Treatment-emergent Adverse Events ( $\geq 10\%$  in Bortezomib-Based Treatment Group) in the Pooled Phase III Studies of Bortezomib-based Combination Induction Treatment in Patients with Previously Untreated Multiple Myeloma Suitable for Stem Cell Transplantation (pooled from three studies)**

MedDRA SOC Preferred Term	Non Bortezomib-Based N = 776		Bortezomib-Based N = 779	
	Total n (%)	Grade $\geq 3$ n (%)	Total n (%)	Grade $\geq 3$ n (%)
<b>General disorders and administration site conditions</b>				
Fatigue	161 (21)	21 (3)	158 (20)	21 (3)
Pyrexia	159 (21)	36 (5)	153 (20)	25 (3)
Oedema peripheral	75 (10)	4 (1)	117 (15)	2 (<1)
Asthenia	91 (12)	10 (1)	110 (14)	16 (2%)
Oedema	61 (8)	1 (<1)	79 (10)	3 (<1)
<b>Gastrointestinal disorders</b>				
Constipation	214 (28)	8 (1)	242 (31)	10 (1)
Nausea	206 (27)	9 (1)	215 (28)	22 (3)
Diarrhoea	110 (14)	6 (1)	133 (17)	23 (3)
Vomiting	87 (11)	6 (1)	95 (12)	18 (2)
<b>Nervous system disorders</b>				
Neuropathy peripheral	54 (7)	4 (1)	147 (19)	20 (3)
Paraesthesia	80 (10)	2 (<1)	101 (13)	11 (1)
Peripheral sensory neuropathy	55 (7)	1 (<1)	101 (13)	19 (2)
<b>Infections and infestations</b>				
Herpes zoster	18 (2)	5 (1)	86 (11)	24 (3)
<b>Blood and lymphatic system disorders</b>				
Thrombocytopenia	171 (22)	27 (4)	239 (31)	63 (8)
Anaemia	222 (29)	77 (10)	211 (27)	55 (7)
Leukopenia	206 (27)	120 (16)	196 (25)	109 (14)
Leukocytosis	84 (11)	3 (<1)	79 (10)	7 (1)
<b>Musculoskeletal and connective tissue disorders</b>				
Back pain	94 (12)	20 (3)	100 (13)	25 (3)
<b>Metabolism and nutrition disorders</b>				
Hypocalcaemia	151 (20)	24 (3)	160 (21)	21 (3)
Enzyme abnormality	105 (14)	7 (1)	131 (17)	8 (1)
Hyperglycaemia	138 (18)	31 (4)	122 (16)	26 (3)
Hypokalaemia	102 (13)	23 (3)	112 (14)	17 (2)
Hyponatraemia	82 (11)	12 (2)	100 (13)	29 (4)
<b>Hepatobiliary disorders</b>				
Hepatic function abnormal	159 (21)	27 (4)	165 (21)	30 (4)
<b>Psychiatric disorders</b>				
Insomnia	82 (11)	6 (1)	96 (12)	6 (1)

### **Randomized Open-Label Phase III Multiple Myeloma Clinical Study (Intravenous Bortezomib)**

The incidence of treatment-emergent adverse events during the study was 100% in bortezomib-treated patients and 98% in dexamethasone-treated patients. Among the 331 bortezomib-treated patients, the most commonly reported adverse events overall were asthenic conditions (61%), diarrhea (58%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting, pyrexia, thrombocytopenia (each 35%), anorexia and decreased appetite (34%), anemia and headache (each 26%), dyspnea (25%), myalgia,

muscle cramps, spasms and stiffness (24%), rash (24%), and cough and paresthesia (each 21%). The most commonly reported adverse events among the 332 patients in the dexamethasone group were psychiatric disorders (49%), asthenic conditions (45%), insomnia (27%), anemia (22%), and diarrhea (21%). Fourteen percent (14%) of patients in the bortezomib treatment arm experienced a Grade 4 adverse event; the most common Grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%) and hypercalcemia (2%). Sixteen percent (16%) of dexamethasone-treated patients experienced a Grade 4 adverse event; the most common toxicity was hyperglycemia (2%).

A total of 144 (44%) patients from the bortezomib treatment arm experienced a serious adverse event (SAE) during the study, as did 144 (43%) dexamethasone-treated patients. An SAE is defined as any event, regardless of causality, that results in death, is life-threatening, requires hospitalization or prolongs a current hospitalization, results in a significant disability or is deemed to be an important medical event. The most commonly reported SAEs in the bortezomib treatment arm were pyrexia (6%), diarrhea (5%), dyspnea and pneumonia (4%), and vomiting (3%). In the dexamethasone treatment group, the most commonly reported SAEs were pneumonia (7%), pyrexia (4%), and hyperglycemia (3%).

A total of 145 patients, including 84 (25%) of 331 patients in the bortezomib treatment group and 61 (18%) of 332 patients in the dexamethasone treatment group were discontinued from the treatment due to adverse events assessed as drug-related by the investigators. Among the 331 bortezomib-treated patients, the most commonly reported drug-related event leading to discontinuation was peripheral neuropathy (8%). Among the 332 patients in the dexamethasone group, the most commonly reported drug-related events leading to treatment discontinuation were psychotic disorder and hyperglycemia (2% each).

Of the 669 patients enrolled in this study, 37% were 65 years of age or older. The incidence of Grade 3 and 4 events was 64%, 78% and 75% for bortezomib patients  $\leq 50$ , 51-64 and  $\geq 65$  years of age, respectively.

Four deaths were considered to be bortezomib related in the Phase III multiple myeloma study: 1 case each of cardiogenic shock, respiratory insufficiency, congestive heart failure and cardiac arrest. Four deaths were considered dexamethasone-related: 2 cases of sepsis, 1 case of bacterial meningitis, and 1 case of sudden death at home.

### **Non-randomized Phase II Relapsed Multiple Myeloma Clinical Studies (Intravenous Bortezomib)**

Two Phase II studies (see *Product Monograph PART II, CLINICAL TRIALS*) evaluated 228 patients with multiple myeloma receiving bortezomib for injection 1.3 mg/m<sup>2</sup>/dose twice weekly for 2 weeks followed by a 10-day rest period (21-day treatment cycle length) for a maximum of 8 treatment cycles.

The most commonly reported adverse events were asthenic conditions (65%), nausea (64%), diarrhea (55%), anorexia and decreased appetite (43%), constipation (43%),

thrombocytopenia (43%), peripheral neuropathy (37%), pyrexia (36%), vomiting (36%), and anemia (32%). Fourteen percent (14%) of patients experienced at least one episode of Grade 4 toxicity, with the most common toxicity being thrombocytopenia (3%) and neutropenia (3%).

During the studies, a total of 113 (50%) of the 228 patients experienced SAEs. The most commonly reported SAEs included pyrexia (7%), pneumonia (7%), diarrhea (6%), vomiting (5%), dehydration (5%), and nausea (4%).

Adverse events thought by the investigator to be drug-related and leading to discontinuation occurred in 18% of patients. The reasons for discontinuation included peripheral neuropathy (5%), thrombocytopenia (4%), diarrhea (2%), and fatigue (2%).

In the Phase II clinical study of 202 patients, 35% of whom were 65 years of age or older, the incidence of  $\geq$  Grade 3 adverse events was 74%, 80% and 85% for bortezomib-treated patients  $\leq$  50, 51-64 and  $\geq$  65 years of age, respectively.

Two deaths were reported and considered by the investigator to be possibly related to study drug: one case of cardiopulmonary arrest and one case of respiratory failure.

Patients from the two Phase II studies who, in the investigators' opinion, would experience additional clinical benefit were allowed to receive bortezomib beyond 8 cycles on an extension study (see **Product Monograph PART II, CLINICAL TRIALS**). Compared to the parent studies, patients in this extension study experienced a greater incidence of selected adverse events including edema overall (41% versus 29%), Grade 4 adverse events (22% versus 5%), and serious adverse events (48% versus 33%). As well, there was a greater incidence of lower limb edema (27% versus 10%), hyperglycemia (19% versus 5%), increased blood creatinine (13% versus 3%), productive cough (13% versus 2%), hypoproteinemia (10% versus 0%) and chest wall pain (10% versus 0%) in this extension study compared to the parent Phase II studies. Most of these adverse events were mild or moderate in intensity, and none was reported as an SAE. Of the commonly reported side effects attributable to bortezomib treatment, there was no evidence of their increase with cumulative dosing.

### ***Mantle Cell Lymphoma***

#### **Non-randomized Phase II Study in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Intravenous Bortezomib)**

Safety data for patients with relapsed/refractory mantle cell lymphoma were evaluated in a Phase II study, which included 155 patients treated with bortezomib at the recommended dose of 1.3 mg/m<sup>2</sup> twice weekly on Days 1, 4, 8 and 11 of a 21-day cycle. The most commonly reported adverse events were asthenic conditions (72%), peripheral neuropathy (55%), constipation (50%), diarrhea (47%), nausea (44%), decreased appetite (39%), vomiting (27%), rash (28%), edema (28%), anemia (17%), dizziness (excluding vertigo) (23%), dyspnea (23%), thrombocytopenia (21%), and insomnia (21%). The safety profile of bortezomib in these patients was similar to that observed in patients with multiple myeloma. Notable differences between the two patient populations were that

thrombocytopenia, neutropenia, anemia, nausea, vomiting and pyrexia were reported more often in the patients with multiple myeloma than in those with mantle cell lymphoma; whereas peripheral neuropathy, rash and pruritis were higher among patients with mantle cell lymphoma compared to patients with multiple myeloma. The most common adverse event leading to the discontinuation of bortezomib-treated patients was peripheral neuropathy (10%).

The most common treatment-emergent adverse drug reactions occurring at  $\geq 10\%$  incidence for Phase III and Phase II relapsed multiple myeloma studies are presented in Table 1.5 and Table 1.6, respectively, by System Organ Class. As well, the most common treatment-emergent adverse drug reactions occurring at  $\geq 10\%$  incidence for the Phase II mantle cell lymphoma study is presented in Table 1.7 by System Organ Class.

**Table 1.5: Most Commonly Reported Adverse Events ( $\geq 10\%$  in Intravenous Bortezomib arm), with Grades 3 and 4 Intensity in the Phase III Multiple Myeloma Randomized Study (N=663)**

System Organ Class	Treatment Group					
	Bortezomib (n=331)			Dexamethasone (n= 332)		
	All Events	[n (%)] Grade 3 Events	Grade 4 Events	All Events	[n (%)] Grade 3 Events	Grade 4 Events
<b>Blood and lymphatic system disorders</b>						
Thrombocytopenia	115 (35)	85 (26)	12 (4)	36 (11)	18 (5)	4 (1)
Anemia NOS	87 (26)	31 (9)	2 (<1)	74 (22)	32 (10)	3 (<1)
Neutropenia	62 (19)	40 (12)	8 (2)	5 (2)	4 (1)	0
<b>Gastrointestinal disorders</b>						
Diarrhea NOS, loose stools	192 (58)	24 (7)	0	70 (21)	6 (2)	0
Nausea	190 (57)	8 (2)	0	46 (14)	0	0
Constipation	140 (42)	7 (2)	0	49 (15)	4 (1)	0
Vomiting NOS	117 (35)	11 (3)	0	20 (6)	4 (1)	0
Abdominal Pain NOS	53 (16)	6 (2)	0	12 (4)	1 (<1)	0
Dyspepsia	32 (10)	2 (<1)	0	28 (8)	0	0
<b>General disorders and administration site conditions</b>						
Asthenia (fatigue, weakness, malaise, fatigue aggravated, lethargy)	201 (61)	39 (12)	1 (<1)	148 (45)	20 (6)	0
Pyrexia	116 (35)	6 (2)	0	54 (16)	4 (1)	1 (<1)
Edema lower limb, edema peripheral, peripheral swelling, edema NOS <sup>‡</sup>	56 (17)	0	0	65 (20)	1 (<1)	0
Rigors	37 (11)	0	0	8 (2)	0	0
Pain NOS	33 (10)	7 (2)	0	12 (4)	2 (<1)	1 (<1)
<b>Infections and infestations</b>						
Nasopharyngitis	45 (14)	1 (<1)	0	22 (7)	0	0
Herpes Zoster (including multi-dermatomal or disseminated)	42 (13)	6 (2)	0	15 (5)	4 (1)	1 (<1)
<b>Metabolism and nutrition disorders</b>						
Anorexia, appetite decreased NOS	112 (34)	9 (3)	0	31 (9)	1 (<1)	0
<b>Musculoskeletal and connective tissue disorders</b>						
Bone pain, bone pain	54 (16)	12 (4)	0	53 (16)	11 (3)	0

System Organ Class	Treatment Group					
	Bortezomib (n=331)			Dexamethasone (n= 332)		
	All Events	[n (%)] Grade 3 Events	Grade 4 Events	All Events	[n (%)] Grade 3 Events	Grade 4 Events
aggravated						
Muscle cramps, muscle spasms, muscle stiffness, myalgia	78 (24)	2 (<1)	0	66 (20)	5 (2)	0
Arthralgia, joint stiffness	49 (15)	3 (<1)	0	35 (11)	5 (2)	0
Pain in the limb	50 (15)	5 (2)	0	24 (7)	2 (<1)	0
Back pain	46 (14)	10 (3)	0	33 (10)	4 (1)	0
Musculoskeletal pain	33 (10)	3 (<1)	0	11 (3)	3 (<1)	0
<b>Nervous system disorders</b>						
Peripheral neuropathy NOS, peripheral neuropathy aggravated, peripheral sensory neuropathy	119 (36)	24 (7)	2 (<1)	28 (8)	1 (<1)	1 (<1)
Headache NOS	85 (26)	3 (<1)	0	43 (13)	2 (<1)	0
Paresthesia, burning sensation NOS	70 (21)	5 (2)	0	28 (8)	0	0
Dizziness (excluding vertigo)	45 (14)	3 (<1)	0	34 (10)	0	0
<b>Psychiatric disorders</b>						
Insomnia	60 (18)	1 (<1)	0	90 (27)	5 (2)	0
<b>Respiratory, thoracic and mediastinal disorders</b>						
Dyspnea NOS, dyspnea exertional	84 (25)	17 (5)	1 (<1)	65 (20)	9 (3)	2 (<1)
Cough	70 (21)	2 (<1)	0	35 (11)	1 (<1)	0
<b>Skin and subcutaneous tissue disorders</b>						
Rash NOS, rash pruritic, rash erythematous, rash generalized, rash macular, rash papular, erythema, urticaria NOS.	79 (24)	6 (2)	0	28 (8)	0	0
<b>Vascular disorders</b>						
Orthostatic hypotension, hypotension NOS, postural hypotension	38 (11)	3 (<1)	0	6 (2)	2 (<1)	1 (<1)
‡ Preferred terms mapped to General Disorders and Administration Site Conditions SOC or Musculoskeletal and Connective Tissue Disorders SOC						

**Table 1.6: Most Commonly Reported (≥10% Overall) Adverse Events Reported from 2 Phase II Clinical Trials in Multiple Myeloma Patients (N=228)**

System Organ Class	Intravenous Bortezomib-Treated Patients at 1.3 mg/m <sup>2</sup> /dose (N=228)		
	All Events n (%)	Grade 3 Events n (%)	Grade 4 Events n (%)
<b>Blood and lymphatic system disorders</b>			
Thrombocytopenia	97 (43)	61 (27)	7 (3)
Anemia NOS or anemia NOS aggravated, hemoglobin decreased, red blood cell count decreased†	74 (32)	21 (9)	0
Neutropenia or neutropenia aggravated	54 (24)	29 (13)	6 (3)

System Organ Class	Intravenous Bortezomib-Treated Patients at 1.3 mg/m <sup>2</sup> /dose (N=228)		
	All Events n (%)	Grade 3 Events n (%)	Grade 4 Events n (%)
<b>Eye disorders</b>			
Vision blurred	25 (11)	1 (<1)	0
<b>Gastrointestinal disorders</b>			
Nausea or nausea aggravated	145 (64)	15 (7)	0
Diarrhea NOS or loose stools	125 (55)	16 (7)	2 (1)
Constipation or constipation aggravated	99 (43)	5 (2)	0
Vomiting NOS	82 (36)	16 (7)	1 (<1)
Abdominal pain NOS, abdominal pain upper or abdominal discomfort	45 (20)	5 (2)	0
Dyspepsia	30 (13)	0	0
<b>General disorders and administration site conditions</b>			
Asthenia (fatigue, weakness, malaise, fatigue aggravated, lethargy)	149 (65)	42 (18)	1 (<1)
Pyrexia	82 (36)	9 (4)	0
Edema peripheral, edema lower limb, peripheral swelling‡	48 (21)	2 (1)	0
Rigors	27 (12)	1 (<1)	0
Pain NOS	22 (10)	3 (1)	0
<b>Infections and infestations</b>			
Upper respiratory tract infection NOS	41 (18)	0	0
Herpes zoster (including multidermatomal or disseminated)	26 (11)	2 (1)	0
Pneumonia NOS	23 (10)	12 (5)	0
<b>Metabolism and nutrition disorders</b>			
Anorexia, appetite decreased NOS	99 (43)	6 (3)	0
Dehydration	42 (18)	15 (7)	0
Weight decreased, failure to thrive <sup>§</sup>	26 (11)	2 (1)	0
<b>Musculoskeletal and connective tissue disorders</b>			
Arthralgia, joint stiffness	63 (28)	11 (5)	0
Pain in the limb	59 (26)	16 (7)	0
Muscle cramps, muscle spasms, muscle stiffness, myalgia	60 (26)	8 (4)	0
Bone pain, bone pain aggravated	39 (17)	11 (5)	0
Back pain	31 (14)	9 (4)	0
<b>Nervous system disorders</b>			
Peripheral neuropathy NOS, peripheral neuropathy aggravated, peripheral sensory neuropathy	84 (37)	31 (14)	0
Headache NOS	63 (28)	8 (4)	0
Dizziness (excluding vertigo)	48 (21)	3 (1)	0
Paresthesia, burning sensation NOS	32 (14)	5 (2)	0
Dysgeusia	29 (13)	1 (<1)	0
Hypoesthesia	26 (11)	1 (<1)	0
<b>Psychiatric disorders</b>			
Insomnia	62 (27)	3 (1)	0
Anxiety NEC	32 (14)	0	0
<b>Respiratory, thoracic and mediastinal disorders</b>			
Dyspnea NOS, dyspnea exertional, dyspnea exacerbated	66 (29)	8 (4)	1 (<1)
Cough	39 (17)	1 (<1)	0
Epistaxis	23 (10)	1 (<1)	0
<b>Skin and subcutaneous tissue disorders</b>			

System Organ Class	Intravenous Bortezomib-Treated Patients at 1.3 mg/m <sup>2</sup> /dose (N=228)		
	All Events n (%)	Grade 3 Events n (%)	Grade 4 Events n (%)
Rash NOS, rash pruritic rash erythematous, rash generalized, rash macular, rash papular, erythema, urticaria NOS	63 (28)	1 (<1)	0
Pruritus NOS, pruritus generalized	28 (12)	0	0
<b>Vascular disorders</b>			
Orthostatic hypotension, hypotension NOS, postural hypotension	27 (12)	8 (4)	0
† Preferred terms mapped to Blood and Lymphatic System Disorders System Organ Class (SOC) or Investigations SOC			
‡ Preferred terms mapped to General Disorders and Administration Site Conditions SOC or Musculoskeletal and Connective Tissue Disorders SOC			
¥ Preferred terms mapped to Investigations SOC or Metabolism and Nutrition Disorders SOC			

**Table 1.7: Most Commonly Reported Adverse Events (≥ 10% overall) Reported in the Phase II Mantle Cell Lymphoma Study**

System Organ Class	Intravenous Bortezomib-Treated Patients at 1.3 mg/m <sup>2</sup> /dose (N=155)	
	All Events n (%)	≥ Grade 3 n (%)
<b>Blood and lymphatic system disorders</b>		
Thrombocytopenia	33 (21)	17 (11)
Anemia	27 (17)	4 (3)
<b>Gastrointestinal disorders</b>		
Constipation	77 (50)	4 (3)
Diarrhea	73 (47)	11 (7)
Nausea	68 (44)	4 (3)
Vomiting	42 (27)	4 (3)
Abdominal pain	24 (15)	8 (5)
<b>General disorders and administration site conditions</b>		
Asthenic conditions	112 (72)	29 (19)
Edema	44 (28)	4 (3)
Pyrexia	30 (19)	2 (1)
<b>Infections and infestations</b>		
Upper respiratory tract infection	24 (15)	1 (<1)
<b>Metabolism and nutrition disorders</b>		
Appetite decreased	60 (39)	5 (3)
<b>Musculoskeletal and connective tissue disorders</b>		
Arthralgia	20 (13)	2 (1)
Myalgia	15 (10)	0
<b>Nervous system disorders</b>		
Peripheral neuropathy†	85 (55)	20 (13)
Dizziness (excluding vertigo)	36 (23)	5 (3)
Headache	26 (17)	0
<b>Psychiatric disorders</b>		
Insomnia	33 (21)	1 (<1)
<b>Respiratory, thoracic and mediastinal disorders</b>		
Dyspnea	35 (23)	7 (5)
Cough	30 (19)	0

System Organ Class	Intravenous Bortezomib-Treated Patients at 1.3 mg/m <sup>2</sup> /dose (N=155)	
	All Events n (%)	≥ Grade 3 n (%)
<b>Skin and subcutaneous tissue disorders</b>		
Rash	43 (28)	4 (3)
<b>Vascular disorders</b>		
Hypotension	23 (15)	5 (3)
† Peripheral neuropathy includes all terms under peripheral neuropathy NEC (peripheral neuropathy NOS, peripheral neuropathy aggravated, peripheral sensory neuropathy and peripheral motor neuropathy, and neuropathy NOS).		

### Randomized Phase III Study in Patients with Previously Untreated Mantle Cell Lymphoma (Intravenous Bortezomib)

Safety data for patients with previously untreated mantle cell lymphoma (MCL) were evaluated in a phase III study, which included 240 patients treated with bortezomib at the recommended dose of 1.3 mg/m<sup>2</sup> in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [VcR-CAP] versus 242 patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]. In general, the safety profile of bortezomib in these patients was similar to that observed in patients with multiple myeloma.

The most commonly reported adverse reactions are presented in Table 1.8. The most common (≥ 10%) Grade 3 or higher adverse reactions were neutropenia (VcR-CAP: 83% vs R-CHOP: 65%), thrombocytopenia (VcR-CAP: 56% vs R-CHOP: 5%), leukopenia (VcR-CAP: 43% vs RCHOP: 27%), lymphopenia (VcR-CAP: 25% vs R-CHOP: 7%), anemia (VcR-CAP: 13% vs RCHOP: 11%), and febrile neutropenia (15% vs 13%).

The incidence of bleeding adverse reactions (≥ Grade 3) associated with low platelet counts (Grade 3 or higher) within the same or prior cycle, up to the end of the bleeding event was 1% (3 patients) in the VcR-CAP treatment arm and <1% (1 subject) in the R-CHOP treatment arm. All of the bleeding events resolved without sequelae in the VcR-CAP arm.

Infections were reported for 31% of patients in the VcR-CAP arm and 23% of the patients in the R-CHOP arm. Respiratory tract and lung infections were reported, with the predominant preferred term of pneumonia (VcR-CAP 8% versus R-CHOP 5%). The incidence of herpes zoster reactivation was 4.6% in the VcR-CAP arm and 0.8% in the R-CHOP arm. Antiviral prophylaxis was mandated by protocol amendment.

Treatment discontinuation due to an adverse drug reaction occurred in 7.9% of subjects in the VcR-CAP arm compared to 5.8% in the R-CHOP arm. The most common adverse reaction leading to discontinuation in the VcR-CAP arm compared to R-CHOP arm was peripheral sensory neuropathy (1.3% vs 0.4%).



**Table 1.8. Most Commonly Reported Adverse Reactions ( $\geq 5\%$ ) with Grades 3 and  $\geq 4$  Intensity in the Phase III Mantle Cell Lymphoma Study of VcR-CAP versus R-CHOP**

System Organ Class Preferred Term	VcR-CAP n=240			R-CHOP n=242		
	Total n (%)	Toxicity Grade 3 n (%)	Toxicity Grade $\geq 4$ n (%)	Total n (%)	Toxicity Grade 3 n (%)	Toxicity Grade $\geq 4$ n (%)
<b>Blood and lymphatic system disorders</b>						
Neutropenia	209 (87)	32 (13)	168 (70)	172 (71)	31 (13)	125 (52)
Leukopenia	116 (48)	34 (14)	69 (29)	87 (36)	39 (16)	27 (11)
Anaemia	106 (44)	27 (11)	4 (2)	71 (29)	23 (10)	4 (2)
Thrombocytopenia	172 (72)	59 (25)	76 (32)	42 (17)	9 (4)	3 (1)
Febrile neutropenia	41 (17)	24 (10)	12 (5)	33 (14)	17 (7)	15 (6)
Lymphopenia	68 (28)	25 (10)	36 (15)	28 (12)	15 (6)	2 (1)
<b>Nervous system disorders</b>						
Peripheral sensory neuropathy	53 (22)	11 (5)	1 (< 1)	45 (19)	6 (3)	0
Neuropathy peripheral	18 (8)	4 (2)	0	18 (7)	2 (1)	0
Hypoesthesia	14 (6)	3 (1)	0	13 (5)	0	0
Paraesthesia	14 (6)	2 (1)	0	11 (5)	0	0
Neuralgia	25 (10)	9 (4)	0	1 (< 1)	0	0
<b>General disorders and administration site conditions</b>						
Fatigue	43 (18)	11 (5)	1 (< 1)	38 (16)	5 (2)	0
Pyrexia	48 (20)	7 (3)	0	23 (10)	5 (2)	0
Asthenia	29 (12)	4 (2)	1 (< 1)	18 (7)	1 (< 1)	0
Oedema peripheral	16 (7)	1 (< 1)	0	13 (5)	0	0
<b>Gastrointestinal disorders</b>						
Nausea	54 (23)	1 (< 1)	0	28 (12)	0	0
Constipation	42 (18)	1 (< 1)	0	22 (9)	2 (1)	0
Stomatitis	20 (8)	2 (1)	0	19 (8)	0	1 (< 1)
Diarrhoea	59 (25)	11 (5)	0	11 (5)	3 (1)	1 (< 1)
Vomiting	24 (10)	1 (< 1)	0	8 (3)	0	0
Abdominal distension	13 (5)	0	0	4 (2)	0	0
<b>Infections and infestations</b>						
Pneumonia	20 (8)	8 (3)	5 (2)	11 (5)	5 (2)	3 (1)
<b>Skin and subcutaneous tissue disorders</b>						
Alopecia	31 (13)	1 (< 1)	1 (< 1)	33 (14)	4 (2)	0
<b>Metabolism and nutrition disorders</b>						
Hyperglycaemia	10 (4)	1 (< 1)	0	17 (7)	10 (4)	0
Decreased appetite	36 (15)	2 (1)	0	15 (6)	1 (< 1)	0
Hypokalaemia	11 (5)	3 (1)	1 (< 1)	6 (3)	1 (< 1)	0
<b>Vascular disorders</b>						
Hypertension	15 (6)	1 (< 1)	0	3 (1)	0	0
<b>Psychiatric disorders</b>						
Insomnia	16 (7)	1 (< 1)	0	8 (3)	0	0

Key: R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone;  
VcR-CAP= BORTEZOMIB, rituximab, cyclophosphamide, doxorubicin, and prednisone.

## **Summary of Clinical Trials of Bortezomib Administered Intravenously versus Subcutaneously in Patients with Relapsed Multiple Myeloma**

The safety and efficacy of bortezomib administered subcutaneously were evaluated in one Phase III study at the recommended dose of 1.3 mg/m<sup>2</sup>. This was a randomized, comparative study of bortezomib intravenous vs. subcutaneous in 222 patients with relapsed multiple myeloma. The safety described below and in Table 1.9 reflects exposure to either bortezomib subcutaneous (n=147) or bortezomib intravenous (n=74).

**Table 1.9: Incidence of Bortezomib Adverse Drug Reactions Reported in ≥ 10% of Patients in the Phase III Relapsed Multiple Myeloma Study Comparing Bortezomib Intravenous (IV) and Subcutaneous (SC)**

MedDRA System Organ Class	Total n (%)	IV (n=74) Toxicity Grade, n (%)		Total n (%)	SC (n=147) Toxicity Grade, n (%)	
		3	>4		3	>4
<b>Blood and lymphatic system disorders</b>						
Anaemia	26 (35)	6 (8)	0	53 (36)	14 (10)	4 (3)
Leukopenia	16 (22)	4 (5)	1 (1)	29 (20)	9 (6)	0
Neutropenia	20 (27)	10 (14)	3 (4)	42 (29)	22 (15)	4 (3)
Thrombocytopenia	27 (36)	8 (11)	6 (8)	52 (35)	12 (8)	7 (5)
<b>Gastrointestinal disorders</b>						
Abdominal pain	8 (11)	0	0	5 (3)	1 (1)	0
Abdominal pain upper	8 (11)	0	0	3 (2)	0	0
Constipation	11 (15)	1 (1)	0	21 (14)	1 (1)	0
Diarrhea	27 (36)	3 (4)	1 (1)	35 (24)	2 (1)	1 (1)
Nausea	14 (19)	0	0	27 (18)	0	0
Vomiting	12 (16)	0	1 (1)	17 (12)	3 (2)	0
<b>General disorders and administration site conditions</b>						
Asthenia	14 (19)	4 (5)	0	23 (16)	3 (2)	0
Fatigue	15 (20)	3 (4)	0	17 (12)	3 (2)	0
Pyrexia	12 (16)	0	0	28 (19)	0	0
<b>Infections and infestations</b>						
Herpes zoster	7 (9)	1 (1)	0	16 (11)	2 (1)	0
<b>Investigations</b>						
Weight decreased	2 (3)	1 (1)	0	22 (15)	0	0
<b>Metabolism and nutrition disorders</b>						
Decreased appetite	7 (9)	0	0	14 (10)	0	0
<b>Musculoskeletal and connective tissue disorders</b>						
Pain in extremity	8 (11)	2 (3)	0	8 (5)	1 (1)	0
Back pain	8 (11)	1 (1)	1 (1)	21 (14)	1 (1)	0
<b>Nervous system disorders</b>						
Headache	8 (11)	0	0	5 (3)	0	0
Neuralgia	17 (23)	7 (9)	0	35 (24)	5 (3)	0
Peripheral sensory neuropathy (NEC)	39 (53)	11 (15)	1 (1)	56 (38)	8 (5)	1 (1)
<b>Psychiatric disorders</b>						
Insomnia	8 (11)	0	0	18 (12)	0	0
<b>Respiratory, thoracic and mediastinal disorders</b>						
Dyspnea	9 (12)	2 (3)	0	11 (7)	2 (1)	0
<b>Vascular disorders</b>						
Hypertension	3 (4)	0	0	14 (10)	3 (2)	0

Note: Percentages in the 'Total' column for each group calculated with the number of subjects in each group as denominator. Percentages of toxicity grade sub-groups calculated with the number of subjects in each group as denominator.

In general, safety data were similar for the subcutaneous and intravenous treatment groups. Differences were observed in the rates of some Grade  $\geq 3$  adverse events. Differences of  $\geq 5\%$  were reported in neuralgia (3% subcutaneous vs. 9% intravenous), peripheral neuropathy (6% subcutaneous vs. 16% intravenous), and thrombocytopenia (13% subcutaneous vs. 19% intravenous).

Six percent of patients were reported to have had an adverse local reaction to SC administration, mostly redness. Only 2 (1%) subjects were reported as having severe reactions. These severe local reactions were 1 case of pruritus and 1 case of redness. These reactions seldom led to dose modifications and all resolved in a median of 6 days.

Dose reductions occurred due to drug related adverse events in 31% of patients in the subcutaneous treatment group compared with 43% of the intravenously treated patients. The most common adverse events leading to a dose reduction included peripheral sensory neuropathy (17% in the subcutaneous treatment group compared with 31% in the intravenous treatment group; and neuralgia (11% in the subcutaneous treatment group compared with 19% in the intravenous treatment group).

#### **Serious Adverse Events and Events Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of Bortezomib Subcutaneous versus Intravenous**

The incidence of serious adverse events was similar for the subcutaneous treatment group (36%) and the intravenous treatment group (35%). The most commonly reported SAEs in the subcutaneous treatment arm were pneumonia (6%) and pyrexia (3%). In the intravenous treatment group, the most commonly reported SAEs were pneumonia (7%), diarrhea (4%), peripheral sensory neuropathy (3%) and renal failure (3%).

In the subcutaneous treatment group, 27 patients (18%) discontinued study treatment due to a drug-related adverse event compared with 17 patients (23%) in the intravenous treatment group. Among the 147 subcutaneously treated patients, the most commonly reported drug-related event leading to discontinuation was peripheral sensory neuropathy (5%) and neuralgia (5%). Among the 74 treated patients in the intravenous treatment group, the most commonly reported drug-related events leading to treatment discontinuation were peripheral sensory neuropathy (9%) and neuralgia (9%).

Two patients in the subcutaneous treatment group and 1 patient (1%) in the intravenous treatment group died due to a drug-related adverse event during treatment. In the subcutaneous group the causes of death were one case of pneumonia and one of sudden death. In the intravenous group the cause of death was coronary artery insufficiency.

### **Serious Adverse Events from Other Clinical Studies (hematological malignancy and solid tumours)**

The following clinically important serious adverse events that are not described above have been reported in clinical trials in patients treated with bortezomib administered as monotherapy or in combination with other chemotherapeutics. These studies were conducted in patients with hematological malignancies and in solid tumours.

**Blood and lymphatic system disorders:** Disseminated intravascular coagulation

**Cardiac disorders:** Angina pectoris, atrial fibrillation aggravated, atrial flutter, bradycardia, sinus arrest, cardiac amyloidosis, cardiac arrest, congestive heart failure, myocardial ischemia, myocardial infarction, pericarditis, pericardial effusion, pulmonary edema, ventricular tachycardia

One case of torsades de pointes (not described above) has been reported in a patient receiving bortezomib; causality has not been established.

**Ear and labyrinth disorders:** Hearing impaired

**Eye disorders:** Diplopia

**Gastrointestinal disorders:** Ascites, dysphagia, fecal impaction, gastroenteritis, gastritis hemorrhagic, gastrointestinal hemorrhage, hematemesis, hemorrhagic duodenitis, ileus paralytic, large intestinal obstruction, paralytic intestinal obstruction, small intestinal obstruction, large intestinal perforation, stomatitis, melena, pancreatitis acute

**General disorders and administration site conditions:** Injection site erythema

**Hepatobiliary:** Cholestasis, hepatic hemorrhage, hyperbilirubinemia, portal vein thrombosis, hepatitis and liver failure

**Immune system disorders:** Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, acute renal failure (proliferative glomerulonephropathy), diffuse polyarthritis and rash

**Infections and infestations:** Aspergillosis, bacteremia, urinary tract infection, herpes viral infection, listeriosis, septic shock, toxoplasmosis, oral candidiasis

**Injury, poisoning and procedural complications:** Skeletal fracture, subdural hematoma

**Metabolism and nutrition disorders:** Hypocalcemia, hyperuricemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia, tumour lysis syndrome

**Nervous system:** Ataxia, coma, dizziness, dysarthria, dysautonomia, encephalopathy, cranial palsy, grand mal convulsion, hemorrhagic stroke, motor dysfunction, spinal cord compression, paralysis, paraplegia, transient ischemic attack

**Psychiatric:** Agitation, confusion, mental status changes, psychotic disorder, suicidal ideation

**Renal and urinary:** Calculus renal, bilateral hydronephrosis, bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, renal failure – acute and chronic, glomerular nephritis proliferative

**Respiratory, thoracic and mediastinal:** Acute respiratory distress syndrome, aspiration pneumonia, atelectasis, chronic obstructive airways disease exacerbated, dysphagia, epistaxis, hemoptysis, hypoxia, lung infiltration, pleural effusion, pneumonitis, respiratory distress, respiratory failure.

**Skin and subcutaneous tissue disorders:** Urticaria, face edema, leukocytoclastic vasculitis

**Vascular:** Cerebrovascular accident, deep venous thrombosis, peripheral embolism, pulmonary embolism, pulmonary hypertension

### **Abnormal Hematologic and Clinical Chemistry Findings**

Hematological abnormalities are expected in patients with advanced multiple myeloma. With bortezomib, cyclical thrombocytopenia was seen, with a general progressive decrease in platelet count during the bortezomib dosing period (Days 1 to 11) and a return to baseline in platelet count during the rest period (Days 12 to 21) in each treatment cycle. A trend towards an increase in hemoglobin and absolute neutrophil count across treatment cycles was noted especially with an improvement in the underlying disease. A trend towards a decrease in the absolute lymphocyte count was noted across the 8 treatment cycles; however, no trend was noted by cycle. Effects on electrolytes and calcium (hyper- and hypokalemia, hyper- and hyponatremia, hyper- and hypocalcemia) and hypophosphatemia, hypochloremia and hypomagnesemia were noted.

### **Post-Market Adverse Drug Reactions**

The following adverse events have been reported from post-marketing experience:

- **Neurologic/psychiatric events:** seizures, mental status changes, encephalopathy, acute psychosis, bilateral hearing loss, dysautonomia, posterior reversible encephalopathy syndrome, autonomic neuropathy, optic neuropathy and blindness, progressive multifocal leukoencephalopathy (John Cunningham [JC] virus infection)
- **Cardiovascular events:** tachycardia, heart failure, cardiac tamponade, pericarditis, cardiac and cardiopulmonary arrest, complete heart block, cardiogenic shock

- **Pulmonary events:** pulmonary hypertension, pneumonitis, respiratory failure, pulmonary alveolar hemorrhage, pleural effusion, acute pulmonary edema, acute diffuse infiltrative pulmonary disease
- **Serious bleeding events:** subarachnoid hemorrhage, intracerebral hemorrhage, disseminated intravascular coagulation, ischemic stroke, ischemic colitis, spinal cord ischemia
- **Hypersensitivity events:** immune complex type diseases, angioedema, anaphylactic reaction
- **Hepatic/biliary/pancreatic abnormalities:** increased transaminases, alkaline phosphatase, gamma-glutamyl transferase, hepatocellular damage, hepatitis, pancreatitis
- **Renal abnormalities:** acute renal failure, nephrotic syndrome, renal tubular acidosis, renal necrosis, hemolytic uremic syndrome, graft loss and renal graft loss
- **Bacterial and viral infections:** sepsis and septic shock, herpes meningoencephalitis, ophthalmic herpes
- **Skin and subcutaneous tissue disorders:** Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute febrile neutrophilic dermatosis (Sweet's syndrome), leukocytoclastic vasculitis
- **Gastrointestinal disorders:** ischemic colitis, paralytic ileus, intestinal obstruction
- **Metabolism and nutrition disorders:** hyper- and hypocalcemia, hyper- and hypokalemia, severe hyponatremia, inappropriate ADH secretion, tumour lysis syndrome
- **Other:** amyloidosis

## DRUG INTERACTIONS

### Drug-Drug Interactions

Bortezomib is a substrate for cytochrome P450 (CYP) 3A4, 2C19, 1A2, 2D6 and 2C9 in human liver microsomes and a weak inhibitor of CYP isozymes 1A2, 2C9, 2D6 and 3A4 ( $IC_{50} \geq 30 \mu M$  or  $11.5 \mu g/mL$ ) and CYP2C19 ( $IC_{50} \geq 18 \mu M$  or  $6.9 \mu g/mL$ ).

A drug-drug interaction study assessing the effect of rifampicin, a potent CYP3A4 inducer, on the pharmacokinetics of IV bortezomib showed a mean bortezomib AUC reduction of 45% based on data from 6 patients. The concomitant use of BORTEZOMIB FOR INJECTION with strong CYP3A4 inducers is therefore not recommended, as efficacy may be reduced. Examples of CYP3A4 inducers are rifampicin, carbamazepine, phenytoin, phenobarbital and St. John's Wort. In the same drug-drug interaction study, the effect of dexamethasone, a weaker CYP3A4 inducer was assessed. There was no significant effect on bortezomib pharmacokinetics based on data from 7 patients.

In a small drug-drug interaction study assessing the effect of ketoconazole, a potent CYP3A inhibitor, the results were variable and the effects of ketoconazole are incompletely known. The study indicated that the bortezomib AUC mean increased by 35% (90% CI: 1.032-1.772 fold), in the presence of ketoconazole, based on data from 12

patients. Therefore, use BORTEZOMIB FOR INJECTION with caution when co-administering with potent CYP3A4 inhibitors such as ketoconazole and ritonavir.

In a drug-drug interaction study assessing the effect of omeprazole, a potent inhibitor of CYP2C19, there was no significant effect on the pharmacokinetics of bortezomib, based on data from 17 patients.

A drug-drug interaction study assessing the effect of melphalan-prednisone on intravenously administered bortezomib showed a 17% increase in mean bortezomib AUC based on data from 21 patients.

During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics. Patients on oral antidiabetic agents receiving BORTEZOMIB FOR INJECTION treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.

### **Drug-Food Interactions**

Interactions with food have not been established.

### **Drug-Herb Interactions**

Interactions with herbal products have not been established.

### **Drug-Laboratory Interactions**

Interactions with results of laboratory tests have not been established.

### **Drug-Lifestyle Interactions**

BORTEZOMIB FOR INJECTION may be associated with fatigue, dizziness, syncope, orthostatic/postural hypotension or blurred vision. Therefore, patients are advised to be cautious when operating machinery, or when driving.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

BORTEZOMIB FOR INJECTION may be administered:

- Intravenously (at a concentration of 1 mg/mL) as a 3 to 5 second bolus injection or
- Subcutaneously (at a concentration of 2.5 mg/mL)

**Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered.**

For subcutaneous administration, the reconstituted solution is injected into the thighs (right or left) or abdomen (right or left). Injection sites should be rotated for successive injections. New injections should be given at least 2.5 cm from an old site and never into areas where the site is tender, bruised, erythematous, or indurated.

If local injection site reactions occur following BORTEZOMIB FOR INJECTION administration subcutaneously, a less concentrated BORTEZOMIB FOR INJECTION solution (1 mg/mL instead of a 2.5 mg/mL) may be administered subcutaneously (see **Reconstitution/Preparation for Intravenous and Subcutaneous Administration** and follow reconstitution instructions for 1 mg/mL). Alternatively, the intravenous route of administration should be considered (see **Reconstitution/Preparation for Intravenous and Subcutaneous Administration**).

In clinical trials, local skin irritation was reported in 5% of patients, but extravasation of bortezomib was not associated with tissue damage. In a clinical trial of subcutaneous bortezomib, a local reaction was reported in 6% of patients as an adverse event, mostly redness.

Treatment must be administered under the supervision of a physician qualified and experienced in the use of antineoplastic agents.

Bortezomib for Injection has not been formally studied in patients with impaired renal function. Patients with compromised renal function should be monitored carefully, especially if creatinine clearance is  $\leq 30$  mL/minute (see **WARNINGS AND PRECAUTIONS** and **ADVERSE REACTIONS**).

Bortezomib has been studied in patients with impaired hepatic function. Patients with mild hepatic impairment do not require a starting dose adjustment and should be treated as per the recommended BORTEZOMIB FOR INJECTION dose. Patients with moderate or severe hepatic impairment should be started on a reduced dose. See **Dose Modification in Patients with Hepatic Impairment** and **WARNINGS AND PRECAUTIONS**.

There is no evidence to suggest that dose adjustments are necessary in elderly patients (see **ADVERSE REACTIONS**).

The safety and effectiveness of BORTEZOMIB FOR INJECTION in children and adolescents have not been established.

#### **Reconstitution/Preparation for Intravenous and Subcutaneous Administration**

BORTEZOMIB FOR INJECTION is a cytotoxic agent. Caution should be used during handling and preparation. Proper aseptic technique should be used since no preservative is present. Use of gloves and other protective clothing to prevent skin contact is recommended.



Different volumes of normal (0.9%) sodium chloride injection USP are used to reconstitute the product for the different routes of administration. The reconstituted concentration of bortezomib for the subcutaneous administration (2.5 mg/mL) is greater than the reconstituted concentration of bortezomib for intravenous administration (1 mg/mL). **Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered (see Dosing Considerations).**

For each 3.5 mg single-use vial of bortezomib, reconstitute with the following volume of normal (0.9%) sodium chloride injection USP based on the route of administration:

**Table 1.10: Reconstitution Volumes and Final Concentration for Intravenous and Subcutaneous Administration**

Vial Size	Route of Administration	Volume of Diluent (normal [0.9%] sodium chloride injection USP)	Final bortezomib concentration (mg/mL)
3.5 mg/vial	Intravenous	3.5 mL	1.0 mg/mL
3.5 mg/vial	Subcutaneous	1.4 mL	2.5 mg/mL

After determining patient body surface area (BSA) in square meters, use the following equations to calculate the total volume (mL) of reconstituted BORTEZOMIB FOR INJECTION to be administered:

**Intravenous Administration (1 mg/mL concentration):**

$$\frac{\text{BORTEZOMIB FOR INJECTION dose (mg/m}^2\text{)} \times \text{patient BSA (m}^2\text{)}}{1 \text{ mg/mL}} = \text{Total BORTEZOMIB FOR INJECTION volume (mL) to be administered}$$

**Subcutaneous Administration (2.5 mg/mL concentration):**

$$\frac{\text{BORTEZOMIB FOR INJECTION dose (mg/m}^2\text{)} \times \text{patient BSA (m}^2\text{)}}{2.5 \text{ mg/mL}} = \text{Total BORTEZOMIB FOR INJECTION volume (mL) to be administered}$$

Stickers that indicate the final bortezomib concentration and whether administration should be subcutaneous only, are provided with each BORTEZOMIB FOR INJECTION vial. These stickers should be placed directly on the syringe of BORTEZOMIB FOR INJECTION once BORTEZOMIB FOR INJECTION is prepared to help alert practitioners of the correct route of administration for BORTEZOMIB FOR INJECTION.

The reconstituted product should be a clear and colourless solution. Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration whenever solution and container permit. If any discolouration or particulate matter is observed, the reconstituted product should not be used.

**Stability:**

BORTEZOMIB FOR INJECTION contains no antimicrobial preservative.

The reconstituted solution should be administered within eight hours of preparation when stored in the original vial or in a syringe at room temperature between 15<sup>0</sup>C to 30<sup>0</sup>C. The total storage time for the reconstituted solution must not exceed eight hours when exposed to normal indoor lighting.

Single-use vials. Discard unused portion.

**Dosage in Previously Untreated Multiple Myeloma****Patients Suitable for Stem Cell Transplantation**

The recommended starting dose of BORTEZOMIB FOR INJECTION, in combination with other medicinal products used for the treatment of multiple myeloma, is 1.3 mg/m<sup>2</sup> body surface area to be administered intravenously twice weekly on days 1, 4, 8 and 11, followed by a rest period of up to 20 days, which is considered a treatment cycle. Three to six cycles should be administered. At least 72 hours should elapse between consecutive doses of BORTEZOMIB FOR INJECTION.

For BORTEZOMIB FOR INJECTION dosage adjustments for transplant eligible patients follow dose modification guidelines described under **Dosage in Relapsed Multiple Myeloma and Relapsed/Refractory Mantle Cell Lymphoma** and **Dose Modification in Patients with Hepatic Impairment**.

For dosing instructions for other medicinal products combined with BORTEZOMIB FOR INJECTION, please see corresponding Product Monographs.

**Patients Not Suitable for Stem Cell Transplantation**

BORTEZOMIB FOR INJECTION (bortezomib) is administered in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles as shown in Table 1.11. In Cycles 1-4, BORTEZOMIB FOR INJECTION is administered twice weekly (Days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5-9, BORTEZOMIB FOR INJECTION is administered once weekly (Days 1, 8, 22 and 29). At least 72 hours should elapse between consecutive doses of BORTEZOMIB FOR INJECTION.

**Table 1.11: Dosage Regimen for Patients with Previously Untreated Multiple Myeloma**

<b>Twice Weekly BORTEZOMIB FOR INJECTION (Cycles 1-4)</b>												
<b>Week</b>	<b>1</b>				<b>2</b>		<b>3</b>	<b>4</b>		<b>5</b>		<b>6</b>
Bortezomib for Injection (1.3 mg/m <sup>2</sup> )	Day 1	-	-	Day 4	Day 8	Day 11	rest period	Day 22	Day 25	Day 29	Day 32	rest period
Melphalan (9 mg/m <sup>2</sup> )	Day 1	Day 2	Day 3	Day 4	-	-	rest period	-	-	-	-	rest period
Prednisone (60 mg/m <sup>2</sup> )	Day 1	Day 2	Day 3	Day 4	-	-	rest period	-	-	-	-	rest period

**Once Weekly BORTEZOMIB FOR INJECTION (Cycles 5-9 when used in combination with Melphalan and Prednisone)**

Week	1				2	3	4	5	6
Bortezomib for Injection (1.3 mg/m <sup>2</sup> )	Day 1	-	-	-	Day 8	rest period	Day 22	Day 29	rest period
Melphalan (9 mg/m <sup>2</sup> ) Prednisone (60 mg/m <sup>2</sup> )	Day 1	Day 2	Day 3	Day 4	-	rest period	-	-	rest period

See *Product Monograph* Part II, CLINICAL TRIALS

**Dose Modification Guidelines for Combination Therapy with BORTEZOMIB FOR INJECTION, Melphalan and Prednisone**

Dose modification and re-initiation of therapy when BORTEZOMIB FOR INJECTION is administered in combination with melphalan and prednisone:

Prior to initiating a new cycle of therapy:

- Platelet count should be  $\geq 70 \times 10^9/L$  and the ANC should be  $\geq 1.0 \times 10^9/L$
- Non-hematological toxicities should have resolved to Grade 1 or baseline

**Table 1.12: Dose Modifications During Subsequent Cycles of Combination BORTEZOMIB FOR INJECTION, Melphalan and Prednisone Therapy**

Toxicity	Dose modification or delay
<b><i>Hematological toxicity during a cycle:</i></b> If prolonged ( $\geq 5$ days) Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle	Consider reduction of the melphalan dose by 25% in the next cycle.
If platelet count $\leq 30 \times 10^9/L$ or ANC $\leq 0.75 \times 10^9/L$ on a BORTEZOMIB FOR INJECTION dosing day (other than day 1)	BORTEZOMIB FOR INJECTION dose should be withheld.
If several BORTEZOMIB FOR INJECTION doses in a cycle are withheld ( $\geq 3$ doses during twice-weekly administration or $\geq 2$ doses during weekly administration)	BORTEZOMIB FOR INJECTION dose should be reduced by 1 dose level (from 1.3 mg/m <sup>2</sup> to 1 mg/m <sup>2</sup> , or from 1 mg/m <sup>2</sup> to 0.7 mg/m <sup>2</sup> )
<b><i>Grade <math>\geq 3</math> non-hematological toxicities</i></b>	BORTEZOMIB FOR INJECTION therapy should be withheld until symptoms of the toxicity have resolved to Grade 1 or baseline. Then, BORTEZOMIB FOR INJECTION may be reinitiated with one dose level reduction (from 1.3 mg/m <sup>2</sup> to 1 mg/m <sup>2</sup> , or from 1 mg/m <sup>2</sup> to 0.7 mg/m <sup>2</sup> ). For BORTEZOMIB FOR INJECTION - related neuropathic pain and/or peripheral neuropathy, hold and/or modify BORTEZOMIB FOR INJECTION as outlined in Table 1.13.

Please refer to the melphalan and prednisone Product Monographs for additional information.

## **Dosage in Relapsed Multiple Myeloma and Relapsed/Refractory Mantle Cell Lymphoma**

The recommended starting dose of bortezomib is 1.3 mg/m<sup>2</sup> body surface area administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). This 3-week period is considered a treatment cycle. For extended therapy beyond 8 cycles, BORTEZOMIB FOR INJECTION may be administered on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35). At least 72 hours should elapse between consecutive doses of BORTEZOMIB FOR INJECTION to minimize drug accumulation.

For tolerability reasons, dose reduction to 1.0 mg/m<sup>2</sup> has been found effective. BORTEZOMIB FOR INJECTION therapy should be withheld at the onset of any Grade 3 non-hematological or any Grade 4 hematological toxicities, excluding neuropathy as discussed below (see **WARNINGS AND PRECAUTIONS**). Once the symptoms of the toxicity have resolved, BORTEZOMIB FOR INJECTION treatment may be re-initiated at a 25% reduced dose (1.3 mg/m<sup>2</sup> reduced to 1.0 mg/m<sup>2</sup>; 1.0 mg/m<sup>2</sup> reduced to 0.7 mg/m<sup>2</sup>). If toxicity is not resolved or if it recurs at the lowest dose, discontinuation of BORTEZOMIB FOR INJECTION must be considered unless the benefit of treatment clearly outweighs the risk.

Treatment with BORTEZOMIB FOR INJECTION may be associated with a dose-related, transient decrease in platelet count. It is recommended that platelets be monitored before each dose, and that therapy be held if platelet counts are  $< 25 \times 10^9/L$  and re-initiated at a reduced dose after resolution (see **WARNINGS AND PRECAUTIONS**).

In a supportive Phase II relapsed multiple myeloma study in which the majority of patients were not refractory and had received less than 2 prior lines of therapy, a dose of 1.0 mg/m<sup>2</sup> was investigated (see **Product Monograph PART II, CLINICAL TRIALS**).

It is recommended that patients with a confirmed complete response receive 2 additional cycles of BORTEZOMIB FOR INJECTION beyond a confirmation. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles of BORTEZOMIB FOR INJECTION therapy.

Currently there are limited data concerning retreatment with BORTEZOMIB FOR INJECTION.

Patients who experience BORTEZOMIB FOR INJECTION-related neuropathic pain and/or peripheral sensory neuropathy, motor neuropathy or autonomic neuropathy are to be managed as presented in Table 1.13. Patients with pre-existing severe neuropathy may be treated with BORTEZOMIB FOR INJECTION only after careful risk/benefit assessment.

**Table 1.13: Recommended Dose Modification for BORTEZOMIB FOR INJECTION-related Neuropathy**

Severity of Neuropathy	Modification of Dose and Regimen
Grade 1 (paresthesia, weakness and/or loss of reflexes) without pain or loss of function	No action
Grade 1 with pain or Grade 2 (interfering with function but not with activities of daily living)	Reduce BORTEZOMIB FOR INJECTION to 1.0 mg/m <sup>2</sup>
Grade 2 with pain or Grade 3 (interfering with activities of daily living)	Withhold BORTEZOMIB FOR INJECTION treatment until symptoms of toxicity have resolved. When toxicity resolves, re-initiate BORTEZOMIB FOR INJECTION treatment and reduce dose to 0.7 mg/m <sup>2</sup> and change treatment schedule to once per week.
Grade 4 (sensory neuropathy which is disabling or motor neuropathy that is life-threatening or leads to paralysis) and/or severe autonomic neuropathy	Discontinue BORTEZOMIB FOR INJECTION

NCI Common Toxicity Criteria

### Dosage in Previously Untreated Mantle Cell Lymphoma

BORTEZOMIB FOR INJECTION is administered intravenously in combination with intravenously infused rituximab, cyclophosphamide, and doxorubicin, and oral prednisone as shown in Table 1.14. BORTEZOMIB FOR INJECTION is administered at 1.3 mg/m<sup>2</sup> body surface area twice weekly for two weeks on days 1, 4, 8, and 11, followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. Six BORTEZOMIB FOR INJECTION cycles are recommended, although for patients with a response first documented at cycle 6, two additional BORTEZOMIB FOR INJECTION cycles may be given. At least 72 hours should elapse between consecutive doses of BORTEZOMIB FOR INJECTION.

Table 1.14: Dosage Regimen for Patients with Previously Untreated Mantle Cell Lymphoma.								
Twice Weekly BORTEZOMIB FOR INJECTION (Cycles 1-6) <sup>a</sup>								
Week	Week 1					Week 2		Week 3
BORTEZOMIB FOR INJECTION (1.3 mg/m <sup>2</sup> )	Day 1	---	---	Day 4	---	Day 8	Day 11	rest period (Day 12-21)
Rituximab (375 mg/m <sup>2</sup> )	Day 1	---	---	---	---	---	---	---
Cyclophosphamide (750 mg/m <sup>2</sup> )	Day 1	---	---	---	---	---	---	---
Doxorubicin (50 mg/m <sup>2</sup> )	Day 1	---	---	---	---	---	---	---
Prednisone (100 mg/m <sup>2</sup> )	Day 1	Day 2	Day 3	Day 4	Day 5	---	---	---

<sup>a</sup>Two additional BORTEZOMIB FOR INJECTION cycles may be given for patients with a first response documented at Cycle 6.

See **Product Monograph PART II, CLINICAL TRIALS**

### Dose adjustments:

Prior to initiating a new cycle of therapy:

- Platelet count should be  $\geq 100 \times 10^9/L$

- Absolute neutrophil count (ANC) should be  $\geq 1.5 \times 10^9/L$
- Hemoglobin should be  $\geq 8 \text{ g/dL}$  ( $\geq 4.96 \text{ mmol/L}$ )
- Non-hematologic toxicity should have recovered to Grade 1 or baseline

Platelet counts should be monitored prior to each dose of BORTEZOMIB FOR INJECTION. Complete blood counts (CBC) with differential should be frequently monitored throughout treatment with BORTEZOMIB FOR INJECTION.

BORTEZOMIB FOR INJECTION treatment must be withheld at the onset of any  $\geq$  Grade 3 BORTEZOMIB FOR INJECTION -related non-hematological toxicities (excluding neuropathy – see Table 1.13) or  $\geq$  Grade 3 hematological toxicities. For dose adjustments, see Table 1.15 below. Colony stimulating factors may be administered for haematologic toxicity according to local standard practice. Platelet transfusion for the treatment of thrombocytopenia may be considered.

**Table 1.15: Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma**

<b>Toxicity</b>	<b>Posology modification or delay</b>
<i>Hematological toxicity</i> <ul style="list-style-type: none"> <li>• <math>\geq</math> Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, or a platelet count <math>&lt; 10 \times 10^9/L</math></li> </ul>	BORTEZOMIB FOR INJECTION therapy should be withheld for up to 2 weeks until the patient has an ANC $\geq 0.75 \times 10^9/L$ and a platelet count $\geq 25 \times 10^9/L$ . <ul style="list-style-type: none"> <li>• If, after BORTEZOMIB FOR INJECTION has been held, the toxicity does not resolve, as defined above, then BORTEZOMIB FOR INJECTION must be discontinued.</li> <li>• If toxicity resolves i.e. patient has an ANC <math>\geq 0.75 \times 10^9/L</math> and a platelet count <math>\geq 25 \times 10^9/L</math>, BORTEZOMIB FOR INJECTION dose should be reduced by 1 dose level (from <math>1.3 \text{ mg/m}^2</math> to <math>1 \text{ mg/m}^2</math>, or from <math>1 \text{ mg/m}^2</math> to <math>0.7 \text{ mg/m}^2</math>)</li> </ul>
<ul style="list-style-type: none"> <li>• If platelet counts <math>&lt; 25 \times 10^9/L</math>. or ANC <math>&lt; 0.75 \times 10^9/L</math> on a BORTEZOMIB FOR INJECTION dosing day (other than Day 1)</li> </ul>	BORTEZOMIB FOR INJECTION therapy should be withheld for up to 2 days. Doses of drug withheld within a cycle should be skipped, and the dose should not be made up later in the cycle.
<i>Grade <math>\geq 3</math> non-hematological toxicities</i>	BORTEZOMIB FOR INJECTION therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better. Then, BORTEZOMIB FOR INJECTION may be reinitiated with one dose level reduction (from $1.3 \text{ mg/m}^2$ to $1 \text{ mg/m}^2$ , or from $1 \text{ mg/m}^2$ to $0.7 \text{ mg/m}^2$ ).  For BORTEZOMIB FOR INJECTION-related neuropathic pain and/or peripheral neuropathy, hold and/or modify BORTEZOMIB FOR INJECTION as outlined in Table 1.13.

For dosing adjustment instructions for rituximab, cyclophosphamide, doxorubicin, or prednisone, see manufacturer's Product Monographs.

## **Dose Modification in Patients with Hepatic Impairment**

Patients with mild hepatic impairment do not require a starting dose adjustment and should be treated per the recommended BORTEZOMIB FOR INJECTION dose. Patients with moderate or severe hepatic impairment should be started on BORTEZOMIB FOR INJECTION at a reduced dose of 0.7 mg/m<sup>2</sup> per injection during the first cycle, and a subsequent dose escalation to 1.0 mg/m<sup>2</sup> or further dose reduction to 0.5 mg/m<sup>2</sup> may be considered based on patient tolerance (see Table 1.16).

**Table 1.16: Recommended Starting Dose Modification for BORTEZOMIB FOR INJECTION in Patients with Hepatic Impairment**

	<b>Bilirubin Level</b>	<b>SGOT (AST) Levels</b>	<b>Modification of Starting Dose</b>
Mild	≤ 1.0x ULN	> ULN	None
	> 1.0x – 1.5x ULN	Any	None
Moderate	> 1.5x – 3x ULN	Any	Reduce BORTEZOMIB FOR INJECTION to 0.7 mg/m <sup>2</sup> in the first cycle. Consider dose escalation to 1.0 mg/m <sup>2</sup> or further dose reduction to 0.5 mg/m <sup>2</sup> in subsequent cycles based on patient tolerability.
Severe	> 3x ULN	Any	

Abbreviations: SGOT = Serum Glutamic Oxaloacetic Transaminase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal range

## **Missed Dose**

A minimum of 72 hours is required between doses. In a Day 1, 4, 8 and 11 dose schedule, if Day 4, 8 or 11 dose is missed, that dose is not made up.

## **OVERDOSAGE**

Cardiovascular safety pharmacology studies in monkeys and dogs show that single IV doses approximately two to three times the recommended clinical dose on a mg/m<sup>2</sup> basis are associated with hypotension, increases in heart rate, decreases in contractility, altered temperature control and death. The decreased cardiac contractility and hypotension responded to acute intervention with positive inotropic or pressor agents. In dog studies, increases in the QT and corrected QT interval were observed at lethal doses (see ***Product Monograph PART II, DETAILED PHARMACOLOGY***).

Accidental overdosage of at least twice the recommended dose has been associated with the acute onset of symptomatic hypotension and thrombocytopenia with fatal outcomes.

There is no known specific antidote for BORTEZOMIB FOR INJECTION overdosage. In the event of an overdosage, the patient's vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors, and/or inotropic agents) and body temperature (see **WARNINGS AND PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**).

For management of a suspected drug overdose, contact your regional Poison Control Centre.

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis which can affect multiple signalling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death.

The mechanism of action of bortezomib suggests that it should be active in MCL. Proteasome inhibition blocks degradation of I $\kappa$ B and inhibits NF $\kappa$ B. NF $\kappa$ B activates transcription of many genes that inhibit apoptosis and promote proliferation in lymphoma cells. Proteasome inhibition also leads to accumulation of p27 and other cyclin D kinase inhibitors. Low levels of p27 correlate with poor survival in MCL.

### **Pharmacodynamics**

Bortezomib is a selective, reversible proteasome inhibitor and experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types. Bortezomib causes a reduction of tumour growth *in vivo* in many preclinical tumour models, including multiple myeloma.

### **Pharmacokinetics**

Following intravenous bolus administration of 1.0 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup> doses to 24 patients with multiple myeloma (n=12 per each dose level), the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/mL, respectively. In subsequent doses administered twice weekly, mean maximum observed plasma concentrations ranged from 67 to 106 ng/mL for the 1.0 mg/m<sup>2</sup> dose and 89 to 120 ng/mL for the 1.3 mg/m<sup>2</sup> dose. The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours for the 1.0 mg/m<sup>2</sup> dose, and 49 to 109 hours for the 1.3 mg/m<sup>2</sup> dose. Bortezomib is eliminated more rapidly following the first dose compared to subsequent doses. Mean total body clearances were 102 and 112 L/h following the first dose for doses of 1.0 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup>, respectively, and ranged from 15 to 32 L/h following subsequent doses for doses of 1.0 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup>, respectively (see ***Product Monograph PART II, DETAILED PHARMACOLOGY, Clinical Pharmacology***).



In the PK/PD substudy in a Phase III trial, following an intravenous bolus or subcutaneous injection of a 1.3 mg/m<sup>2</sup> dose to multiple myeloma patients (n=14 for IV, n=17 for SC), the total systemic exposure after repeat dose administration (AUC<sub>last</sub>) was comparable for subcutaneous and intravenous administration. The C<sub>max</sub> after SC administration (20.4 ng/mL) was lower than IV (223 ng/mL).

**Absorption:** When administered intravenously, BORTEZOMIB FOR INJECTION has 100% bioavailability.

**Distribution:** The mean distribution volume of bortezomib ranged from 489 to 1884 L/m<sup>2</sup> following single- or repeat-dose intravenous administration of 1.0 mg/m<sup>2</sup> or 1.3 mg/m<sup>2</sup> to patients with multiple myeloma. This suggests that bortezomib distributes widely to peripheral tissues. *In vitro* bortezomib binding to human plasma protein averaged 83% over a concentration range of 10 to 1000 ng/mL.

**Metabolism:** Bortezomib is primarily metabolized via cytochrome P450-mediated deboronation to metabolites that subsequently are hydroxylated. *In vitro* studies indicate that CYP3A4 and 2C19 are quantitatively the major isoforms with CYP1A2, 2C9 and 2D6 having a minor contribution to the overall metabolism of bortezomib. Evaluated deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors. Pooled plasma data from 8 patients at 10 min and 30 min after dosing indicate that the plasma levels of metabolites are low compared to the parent drug.

**Elimination:** The pathway of elimination of bortezomib has not been characterized in humans. The predominant route of elimination is biliary excretion in the rat whereas in the monkey, renal elimination is higher than biliary/fecal elimination.

### **Special Populations and Conditions**

#### **Gender and Race, Pediatrics, Geriatrics and Renal Insufficiency:**

There are no data on effects of bortezomib on the pharmacokinetics in these special populations and conditions.

#### **Hepatic Impairment:**

The effect of hepatic impairment (see **DOSAGE AND ADMINISTRATION**, Table 1.9 for definition of hepatic impairment) on the pharmacokinetics of bortezomib was assessed in 60 cancer patients at bortezomib doses ranging from 0.5 to 1.3 mg/m<sup>2</sup>. When compared to patients with normal hepatic function, mild hepatic impairment did not alter dose-normalized bortezomib AUC. However, the dose-normalized mean AUC values were increased by approximately 60% in patients with moderate or severe hepatic impairment. A lower starting dose is recommended in patients with moderate or severe hepatic impairment, and those patients should be monitored closely.

### **STORAGE AND STABILITY**

BORTEZOMIB FOR INJECTION contains no antimicrobial preservative.

**Storage Conditions for the Powder for injection:**

Unopened vials may be stored between 15 and 30°C. Retain in original package to protect from light.

**Storage Conditions for the Reconstituted solution:**

The reconstituted solution should be administered within eight hours of preparation when stored in the original vial or in a syringe at room temperature between 15<sup>0</sup>C to 30<sup>0</sup>C. The total storage time for the reconstituted solution must not exceed eight hours when exposed to normal indoor lighting.

Single-use vials. Discard unused portion.

**SPECIAL HANDLING INSTRUCTIONS**

BORTEZOMIB FOR INJECTION (bortezomib) is a cytotoxic agent. Caution should be used during handling and preparation. Proper aseptic technique should be used since no preservative is present. Use of gloves and other protective clothing to prevent skin contact is recommended.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**



BORTEZOMIB FOR INJECTION (bortezomib) is supplied in individually cartoned 13.5 mL vials containing 3.5 mg of bortezomib, as a white to off-white cake or powder. The only non-medicinal ingredient is mannitol.

The vial stopper is free of natural rubber latex.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance:

	Boronic Acid (biologically active moiety)	Cyclic Anhydride
Proper Name:	Bortezomib	Not Available
Chemical Name:	[(1R)-3-methyl-1-[[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid	<i>N,N',N''</i> -[2,4,6-Boroxintriyltris [[(1R)-3-methylbutylidene]imino [(1S)-2-oxo-1-(phenylmethyl)-2,1-ethanediyl]]] trispyrazinecarboxamide
Molecular Formula:	C <sub>19</sub> H <sub>25</sub> BN <sub>4</sub> O <sub>4</sub>	C <sub>57</sub> H <sub>69</sub> B <sub>3</sub> N <sub>12</sub> O <sub>9</sub>
Molecular Mass:	384.24 g/mol	1098.67 g/mol
Structural Formula:		

**Physicochemical properties:** Bortezomib is a modified dipeptidyl boronic acid. The product is provided as a mannitol boronic ester which, in reconstituted form, consists of the mannitol ester in equilibrium with its hydrolysis product, the monomeric boronic acid. The drug substance exists in its cyclic anhydride form as a trimeric boroxine.

Bortezomib is a white to off-white powder. The solubility of bortezomib, as the monomeric boronic acid, in water is 3.3-3.8 mg/mL over a pH range of 2-6.5.

## CLINICAL TRIALS

### **Randomized, Open-Label Clinical Study in Patients with Previously Untreated Multiple Myeloma (Front-Line Therapy)**

A prospective Phase III, international, randomized (1:1), open-label clinical study of 682 patients was conducted to determine whether a combination of intravenous bortezomib with oral melphalan and prednisone represented a major improvement in time to progression (TTP) when compared to oral melphalan and prednisone in patients with previously untreated multiple myeloma.

In the VMP treatment group during Cycles 1 to 4, subjects received bortezomib 1.3 mg/m<sup>2</sup> as an i.v. bolus injection on Days 1, 4, 8, 11, 22, 25, 29, and 32 followed by a 10-day rest period (Days 33 to 42), and oral melphalan 9 mg/m<sup>2</sup> and oral prednisone 60 mg/m<sup>2</sup> once daily on Days 1 to 4, followed by a 38-day rest period (Days 5 to 42). During Cycles 5 to 9, subjects received bortezomib 1.3 mg/m<sup>2</sup> as an i.v. bolus injection on Days 1, 8, 22, and 29 followed by a 13-day rest period (Days 30 to 42), and oral melphalan 9 mg/m<sup>2</sup> and oral prednisone 60 mg/m<sup>2</sup> once daily on Days 1 to 4, followed by a 38-day rest period (Days 5 to 42).

Patients in the MP treatment group received oral melphalan 9 mg/m<sup>2</sup> and oral prednisone 60 mg/m<sup>2</sup> once daily on Days 1 to 4, followed by a 38-day rest period (Days 5 to 42) during the Cycles 1-9.

Treatment was administered for a maximum of 9 cycles (approximately 54 weeks) and was discontinued early for disease progression or unacceptable toxicity (see **Product Monograph PART I, DOSAGE AND ADMINISTRATION**). Baseline demographics and patient characteristics are summarized in Table 2.1.

**Table 2.1: Summary of Baseline Patient and Disease Characteristics in the VISTA Study**

<b>Patient Characteristics</b>	<b>VMP N=344</b>	<b>MP N=338</b>
Median age in years (range)	71.0 (57, 90)	71.0 (48, 91)
Gender: male/female	51% / 49%	49% / 51%
Race: Caucasian/asian/black/other	88% / 10% / 1% / 1%	87% / 11% / 2% / 0%
Karnofsky performance status score ≤ 70	35%	33%
Hemoglobin < 100 g/L	37%	36%
Platelet Count < 75 x 10 <sup>9</sup> /L	<1%	1%
<b>Disease Characteristics</b>		
Type of myeloma (%): IgG/IgA/Light chain	64% / 24% / 8%	62% / 26% / 8%
Median β <sub>2</sub> -microglobulin (mg/L)	4.2	4.3
Median albumin (g/L)	33.0	33.0
Creatinine clearance ≤ 30 mL/min [n (%)]	20 (6%)	16 (5%)
<b>ISS Staging n (%)</b>		
I	64 (19)	64 (19)
II	161 (47)	159 (47)
III	119 (35)	115 (34)

VMP= bortezomib, melphalan, prednisone; MP=melphalan, prednisone

At the time of the third pre-specified interim analysis, the primary endpoint, time to progression, was met and patients in the MP arm were offered VMP treatment. TTP was defined as the time from randomization to the date of the first observation of either disease progression or relapse from immunofixation-negative CR. PFS, a secondary endpoint, was defined as the time between randomization and either disease progression or death, whichever occurred first. Survival continued to be followed after the interim analysis. Median follow-up was 16.3 months, with an additional follow-up of overall survival at 60.1 months. Efficacy results are presented in Table 2.2 and Figures 2.1, 2.2 and 2.3.

**Table 2.2: Summary of Efficacy Analyses in the Phase III Previously Untreated Multiple Myeloma Study<sup>†</sup>**

Efficacy Endpoint	VMP N=344	MP N=338	p-value	Odds Ratio <sup>h</sup>
Time to Progression				
Events n (%)	101 (29)	152 (45)		
Median <sup>a</sup> (95% CI)	20.7 mo (17.6, 24.7)	15.0 mo (14.1, 17.9)	0.000002 <sup>c</sup>	
Hazard ratio <sup>b</sup> (95% CI)	0.54 (0.42, 0.70)			
Progression-free Survival				
Events n (%)	135 (39)	190 (56)		
Median <sup>a</sup> (95% CI)	18.3 mo (16.6, 21.7)	14.0 mo (11.1, 15.0)	0.00001 <sup>c</sup>	
Hazard ratio <sup>b</sup> (95% CI)	0.61 (0.49, 0.76)			
Overall Survival <sup>l</sup>				
Events (deaths) n (%)	176 (51.2)	211 (62.4)	0.00043 <sup>c</sup>	
Median <sup>a</sup> (95% CI)	56.4 mo (52.8, 60.9)	43.1 mo (35.3, 48.3)		
Hazard ratio <sup>b</sup> (95% CI)	0.695 (0.567, 0.852)			
Response Rate				
Population <sup>d</sup> n=668	n=337	n=331		
CR <sup>e</sup> n (%)	102 (30)	12 (4)	<10 <sup>-10c</sup>	11.2 (6.1, 20.6)
PR <sup>e</sup> n (%)	136 (40)	103 (31)		
nCR n (%)	5 (1)	0		
CR + Pr <sup>e</sup> n (%)	238 (71)	115 (35)	<10 <sup>-10f</sup>	4.5 (3.2, 6.2)
CR + Pr <sup>e</sup> + MR n (%)	270 (80)	187 (56)	<10 <sup>-7c</sup>	3.2 (2.2, 4.5)
Reduction in Serum M-protein				
Population <sup>g</sup> n=667	n=336	n=331		
>=90% n (%)	151 (45)	34 (10)		
Time to First Response in CR + PR				
Median	1.4 mo	4.2 mo		
Time to Best Response in CR + PR				
Median	2.3 mo	4.9 mo		
Time to CR				
Median	4.2 mo	5.3 mo		
Median <sup>a</sup> Response Duration				
CR <sup>e</sup>	24.0 mo	12.8 mo		
CR + PR <sup>e</sup>	19.9 mo	13.1 mo		
Time to Next Therapy				

Efficacy Endpoint	VMP N=344	MP N=338	p-value	Odds Ratio <sup>b</sup>
Events n (%)	224 (65.1)	260 (76.9)		
Median <sup>a</sup> (95% CI)	27.0 mo (24.7, 31.1)	19.2 mo (17.0, 21.0)	<0.000001 <sup>1,c</sup>	
Hazard ratio <sup>b</sup> (95% CI)	0.557 (0.462, 0.671)			

<sup>†</sup> all results are based on the analysis performed at a median follow-up duration of 16.3 month except for the overall survival analysis that was performed at a median follow-up duration of 60.1 months

CR=complete response; nCR= near complete response; PR= partial response; MR = minimal response

<sup>a</sup> Kaplan-Meier estimate.

<sup>b</sup> Hazard ratio estimate is based on a Cox proportional-hazard model adjusted for stratification factors: beta<sub>2</sub>-microglobulin, albumin, and region. A hazard ratio less than 1 indicates an advantage for VMP

<sup>c</sup> nominal p-value based on the stratified log-rank test adjusted for stratification factors: beta<sub>2</sub>-microglobulin, albumin, and region

<sup>d</sup> Response population includes patients who had measurable disease at baseline

<sup>e</sup> EBMT criteria


<sup>f</sup> p-value for Response Rate (CR + PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors

<sup>g</sup> All randomized patients with secretory disease

<sup>h</sup> Mantel-Haenszel estimate of the common odds ratio for stratified tables is used.

<sup>i</sup> Actual p-value is less than 10<sup>-10</sup>

<sup>j</sup> Survival update based on a median duration of follow-up of 60.1 months.




A survival update was performed with a median duration of follow-up at 60.1 months. A significant survival benefit favouring the VMP treatment group was demonstrated (hazard ratio=0.695; p=0.00043) (see Table 2.2 and Figure 2.2). The median survival in MP treatment group is estimated at 43.1 months, while the median survival on the VMP treatment group is estimated at 56.4 months. The 1-year, 2-year, 3-year and 5-year survival rates based on Kaplan-Meier estimates in the VMP and MP treatment groups are presented in Table 2.3.

**Table 2.3: Summary of 1-, 2-, 3- and 5-Year Survival Benefit in Previously Untreated Patients Based on Kaplan-Meier Estimate**


Efficacy Endpoint	VMP (N=344)	MP (N=338)
<b>1-Year Survival %</b> (95% CI)	88.6 (85.2, 92.0)	81.7 (77.5, 85.9)
<b>2-Year Survival %</b> (95% CI)	77.6 (73.1, 82.2)	68.7 (63.7, 73.8)
<b>3-Year Survival %</b> (95% CI)	68.5 (63.2, 73.7)	54.0 (48.2, 59.8)
<b>5-Year Survival %</b> (95% CI)	46.0% (40.3, 51.8)	34.4% (28.9, 39.9)

VMP=bortezomib, melphalan, prednisone; MP= melphalan, prednisone

**Figure 2.2: Overall Survival Based on Kaplan-Meier Estimate  
VMP vs. MP**



**Figure 2.3: Progression-Free Survival  
Vc-MP vs. MP**



To explore the association of response status (CR, PR, or no response) over-time on the long-term outcomes, including TTP, PFS, and OS, multivariate Cox regression analyses with time-dependent covariates were performed that also adjusted for baseline prognostic factors. Strong associations were seen between response (CR + PR) and longer TTP, PFS, and OS, and there was incremental benefit in terms of those outcomes for the achievement of CR compared with PR.

### Subgroup Analyses

TTP, PFS and OS were evaluated relative to baseline stratification factors, demographic data (sex, race, and age) and disease characteristics (ISS staging and bone marrow cytogenetic abnormalities). The pre-specified analyses of the TTP, PFS and OS across all subgroups were consistent with the overall analyses of these endpoints. The hazard ratios for most subgroups (age, sex, race, ISS staging and bone marrow cytogenetic abnormalities) were consistently  $<1$ , demonstrating a survival benefit for subjects in the Vc-MP treatment group compared with the MP treatment group. At the 5-year update, the hazard ratios for two small subgroups (North American subgroup,  $n=32$ ; high risk cytogenetic subgroup,  $n=39$ ) were slightly greater than 1.

TTP, PFS, OS, ORR and CR were evaluated for 3 renal function categories ( $\leq 30$  mL/min; 31 to 60 mL/min and  $>60$  mL/min). For all endpoints the benefit of VMP over MP is maintained in all 3 renal function subgroups. The hazard ratios for all subgroups were consistently  $<1$ , demonstrating a benefit for subjects in the VMP treatment group compared with the MP treatment group for all 3 renal function subgroups.




## **Randomized, Open-Label Clinical Studies in Patients with Previously Untreated Multiple Myeloma who are Suitable for Stem Cell Transplantation**

A Phase III trial (IFM-2005-01) was conducted to demonstrate the safety and efficacy of bortezomib as part of combination therapy for induction prior to stem cell transplantation in patients with previously untreated multiple myeloma. Bortezomib was administered intravenously in this study. Patients were randomized to either bortezomib/dexamethasone (VcD) or vincristine/doxorubicin/dexamethasone (VAD) as follows (Figure 2.4):

- VcD (n=121): subjects received four 21-day cycles of bortezomib/dexamethasone.
- VcD + DCEP (n=119): subjects received four 21-day cycles of bortezomib/dexamethasone and two cycles of induction intensification with dexamethasone, cyclophosphamide, etoposide or etoposide phosphate, and cis-platinum (DCEP)
- VAD (n=121): subjects received four 28-day cycles of VAD
- VAD + DCEP (n=121): subjects received four 28-day cycles of VAD and two cycles of induction intensification with DCEP.

**Figure 2.4: IFM 2005-01 study design.**



AlloSCT = allogeneic stem cell transplantation; DCEP = dexamethasone, cyclophosphamide, etoposide or etoposide phosphate, and cis-platinum; G-CSF = granulocyte-colony stimulating factor; HDM = high-dose melphalan; HLA = human leukemia antigen haplotype; SCT = stem cell transplant; VAD = vincristine, doxorubicin, and dexamethasone; VcD = bortezomib (1.3 mg/m<sup>2</sup>) and dexamethasone

<sup>a</sup> Subjects could receive up to 2 SCTs. Subjects with a less than very good partial response (VGPR) 1 to 3 months after the first SCT were eligible to receive a second SCT. Subjects with less than a partial response (PR) received a second SCT. Subjects with a PR received a second stem cell transplant; unless the subject had a donor with a matching HLA haplotype, in which case, AlloSCT was performed.

In the VcD treatment group during Cycles 1-4, subjects received bortezomib 1.3 mg/m<sup>2</sup> as i.v. bolus injections on Days 1, 4, 8 and 11, and dexamethasone 40 mg p.o once daily on Days 1 to 4 and 9-12 in Cycle 1 and Cycle 2 and Days 1 to 4 for Cycle 3 and Cycle 4.

Subjects in the VAD treatment group received vincristine 0.4 mg and doxorubicin 9 mg/m<sup>2</sup> as a continuous intravenous infusion on Days 1 to 4 for all cycles, and dexamethasone 40 mg p.o once daily on Days 1 to 4, 9-12, and 17 to 20 in Cycle 1 and Cycle 2 and Days 1 to 4 for Cycle 3 and Cycle 4.

Subjects who underwent induction intensification received, on Days 1 to 4 for two cycles, dexamethasone 40 mg/day p.o, as well as cyclophosphamide 400 mg/m<sup>2</sup>/day, etoposide or etoposide phosphate 40 mg/m<sup>2</sup>/day and cis-platinum 15 mg/m<sup>2</sup>/day as continuous intravenous infusion.

Baseline demographics and patient characteristics are summarized in Table 2.4.

**Table 2.4: Summary of Baseline Patient and Disease Characteristics in the IFM 2005-01 Study**

Patient Characteristics	VAD groups N = 242	VcD Groups N = 240
Median age in years (range)	55.3 (26, 65)	57.0 (31, 65)
< 55 years of age, n (%)	92 (38)	101 (42)
≥ 55 years of age, n (%)	150 (62)	139 (58)
Gender: male/female	52% / 48%	58% / 42%
WHO performance status, n (%)		
0	99 (44)	93 (42)
1	101 (45)	97 (44)
2	22 (10)	28 (13)
3	2 (1)	2 (1)
Hemoglobin < 80 g/L	7%	7%
Platelet count < 50 x 10 <sup>9</sup> /L, n (%)	2 (1)	1 (<1)
Disease Characteristics		
Type of myeloma (%): IgG/IgA/Light Chain	62/22/13	60/22/15
Median B <sub>2</sub> -microglobulin (mg/L)	3.44	3.5
Median albumin (g/dL)	4.0	3.9
Creatinine clearance < 60 mL/min [n (%)]	63 (26)	53 (23)
ISS Staging n (%)		
I	100 (42)	102 (43)
II	83 (35)	78 (33)
III	55 (23)	60 (25)

VcD = bortezomib, dexamethasone

VAD = vincristine, doxorubicin, dexamethasone

Efficacy results from Study IFM-2005-01 are summarized in Table 2.5:

**Table 2.5: Primary efficacy results for IFM 2005-01 (Phase III Study of Bortezomib (i.v.) and dexamethasone (p.o.) Combination Induction Treatment in Patients with Previously Untreated Multiple Myeloma Suitable for Stem Cell Transplantation)**

Efficacy Endpoint Category	VAD (n = 242)		VcD (n = 240)		Odds Ratio <sup>a</sup>	P-value <sup>b</sup>
	N (%)	95% CI for %	N (%)	95% CI for %		
<b>Post-Induction Response Rate, n (%)</b>						
Complete Response (CR)	3 (1.2)	0.3, 3.6	13 (5.4)	2.9, 9.1	4.71 (1.31, 16.93)	0.01
Near CR (nCR)	12 (5.0)	2.6, 8.5	22 (9.2)	5.8, 13.5		
CR + nCR	15 (6.2)	3.5, 10.0	35 (14.6)	10.4, 19.7	2.58 (1.37, 4.85)	0.03
Very good partial response (VGPR)	21 (8.7)	5.5, 13.0	54 (22.5)	17.4, 28.3		
CR + nCR + VGPR	36 (14.9)	10.6, 20.0	89 (37.1)	31.0, 43.5	3.36 (2.16, 5.21)	< 0.001
Partial Response (PR)	111 (45.9)	39.5, 52.4	96 (40.0)	33.8, 46.5		
Overall response rate (CR + nCR + VGPR + PR)	147 (60.7)	54.3, 66.9	185 (77.1)	71.2, 82.2	2.18 (1.46, 3.24)	< 0.001
Minimal Response (MR)	35 (14.5)	10.3, 19.5	18 (7.5)	4.5, 11.6		
No Change	27 (11.2)	7.5, 15.8	10 (4.2)	2.0, 7.5		
Progressive Disease	10 (4.1)	2.0, 7.5	12 (5.0)	2.6, 8.6		
Not evaluable	23 (9.5)	6.1, 13.9	15 (6.3)	3.5, 10.1		

VAD = vincristine, doxorubicin, dexamethasone

VcD = bortezomib dexamethasone

a Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. Note: An odds ratio > 1 indicates an advantage for the VcD group.

b P-value from the Cochran Mantel-Haenszel chi-squared test.

### **Randomized, Open-Label Clinical Study in Relapsed or Refractory Multiple Myeloma comparing Bortezomib IV to Dexamethasone**

A prospective Phase III, international, randomized (1:1), stratified, open-label clinical trial enrolling 669 patients was designed to determine whether bortezomib resulted in improvement in time to progression (TTP) compared to high-dose dexamethasone in patients with progressive multiple myeloma who had received 1 to 3 prior therapies. Patients considered to be refractory to prior high-dose dexamethasone were excluded, as were those with baseline Grade  $\geq 2$  peripheral neuropathy or platelet counts  $< 50 \times 10^9/L$ . A total of 627 patients were evaluable for response. The study excluded patients with a corrected serum calcium of  $\geq 3.5$  mmol/L. All patients with hypercalcemia were required to receive intravenous bisphosphonates concomitantly with bortezomib or dexamethasone (depending on treatment randomization).

Stratification factors were based on the number of lines of prior therapy the patient had previously received (1 previous line versus more than 1 line of therapy), time of progression relative to prior treatment (progression during or within 6 months of stopping their most recent therapy versus relapse > 6 months after receiving their most recent therapy), and screening  $\beta_2$ -microglobulin levels ( $\leq 2.5$  mg/L versus  $> 2.5$  mg/L).

Baseline patient and disease characteristics are summarized in Table 2.6.

**Table 2.6: Summary of Baseline Patient and Disease Characteristics in the Phase III Multiple Myeloma Trial**

	<b>Bortezomib N=333</b>	<b>Dexamethasone N=336</b>
<b>Patient Characteristics</b>		
Median age in years (range)	62.0 (33, 84)	61.0 (27, 86)
Gender: male/female	56% / 44%	60% / 40%
Race: Caucasian/ Black/other	90% / 6% / 4%	88% / 7% / 5%
Karnofsky performance status score $\leq$ 70	13%	17%
Hemoglobin < 100 g/L	32%	28%
Platelet Count <75 x 10 <sup>9</sup> /L	6%	4%
<b>Disease Characteristics</b>		
Type of myeloma (%): IgG/IgA/Light chain	60% / 23% / 12%	59% / 24% / 13%
Median $\beta_2$ -microglobulin (mg/L)	3.7	3.6
Median albumin (g/L)	39.0	39.0
Creatinine clearance $\leq$ 30 mL/min [n (%)]	17 (5%)	11 (3%)
<b>Median Duration of Multiple Myeloma Since Diagnosis (Years)</b>	3.5	3.1
<b>Number of Prior Therapeutic Lines of Treatment</b>		
Median	2	2
1 prior line	40%	35%
> 1 prior line	60%	65%
All Patients	(N=333)	(N=336)
Any prior steroids, e.g., dexamethasone, VAD	98%	99%
Any prior anthracyclines, e.g., VAD, mitoxantrone	77%	76%
Any prior alkylating agents, e.g., MP, VBMCP	91%	92%
Any prior thalidomide therapy	48%	50%
Prior vinca alkaloids	74%	72%
Prior stem cell transplant/other high-dose therapy	67%	68%
Prior experimental or other types of therapy	3%	2%

Patients in the bortezomib treatment group were to receive eight 3-week treatment cycles followed by three 5-week treatment cycles of bortezomib. Within each 3-week treatment cycle, bortezomib 1.3 mg/m<sup>2</sup>/dose alone was administered by IV bolus twice weekly for 2 weeks on Days 1, 4, 8, and 11 followed by a 10-day rest period (Days 12 to 21). Within each 5-week treatment cycle, bortezomib 1.3 mg/m<sup>2</sup>/dose alone was administered by IV bolus once weekly for 4 weeks on Days 1, 8, 15, and 22 followed by a 13-day rest period (Days 23 to 35) (see **Product Monograph PART I, DOSAGE AND ADMINISTRATION**).

Patients in the dexamethasone treatment group were to receive four 5-week treatment cycles followed by five 4-week treatment cycles. Within each 5-week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4, 9 to 12, and 17 to 20 followed by a 15-day rest period (Days 21-35). Within each 4-week treatment cycle, dexamethasone 40 mg/day PO was administered once daily on Days 1 to 4 followed by a 24-day rest period (Days 5 to 28). Patients with documented progressive disease on dexamethasone were offered bortezomib at a standard dose and schedule on a companion study.

Following a preplanned interim analysis of time to progression, the dexamethasone arm was halted and all patients randomized to dexamethasone were offered bortezomib,

regardless of disease status. At this time of study termination, a final statistical analysis was performed.

In the bortezomib arm, 34% of patients received at least one bortezomib dose in all 8 of the 3-week cycles of therapy, and 13% received at least one dose in all 11 cycles. The average number of bortezomib doses during the study was 22, with a range of 1 to 44. In the dexamethasone arm, 40% of patients received at least one dose in all 4 of the 5-week treatment cycles of therapy and 6% received at least one dose in all 9 cycles.

The time to event analyses and response rates from the Phase III trial are presented in Table 2.7. Response and progression were assessed using the European Group for Blood and Marrow Transplantation (EBMT) criteria. Complete response (CR) required < 5% plasma cells in the marrow, 100% reduction in M-protein, and a negative immunofixation test (IF-). Partial Response (PR) required ≥ 50% reduction in serum myeloma protein and ≥ 90% reduction of urine myeloma protein on at least 2 occasions for a minimum of at least 6 weeks along with stable bone disease and normal calcium. Near complete response (nCR) was defined as meeting all the criteria for complete response including 100% reduction in M-protein by protein electrophoresis; however, M-protein was still detectable by immunofixation (IF+).

**Table 2.7: Summary of Efficacy Analyses in the Randomized Phase III Previously Treated Multiple Myeloma Study**

Efficacy Endpoint	All Patients		1 Prior Line of Therapy		> 1 Prior Line of Therapy	
	Bortezomib	Dex	Bortezomib	Dex	Bortezomib	Dex
	N=333	N=336	N=132	N=119	N=200	N=217
Time to progression						
Event n (%)	147 (44)	196 (58)	55 (42)	64 (54)	92 (46)	132 (61)
Median <sup>a</sup> (95% CI)	6.2 mo (4.9, 6.9)	3.5 mo (2.8, 4.2)	7.0 mo (6.2, 8.8)	5.5 mo (3.4, 6.3)	4.9 mo (4.2, 6.3)	2.9 mo (2.8, 3.5)
Hazard ratio <sup>b</sup> (95% CI)	0.55 (0.44, 0.69)		0.56 (0.38, 0.81)		0.55 (0.41, 0.72)	
p-value <sup>c</sup>	<0.0001		0.0021		<0.0001	
Response Rate						
Population <sup>d</sup> n=627	n=315	n=312	n=128	n=110	n=187	n=202
CR <sup>e</sup> n (%)	20 (6)	2 (<1)	8 (6)	2 (2)	12 (6)	0 (0)
PR <sup>e</sup> n (%)	101 (32)	54 (17)	49 (38)	27 (25)	52 (28)	27 (13)
nCR <sup>e,f</sup> n (%)	21 (7)	3 (<1)	8 (6)	2 (2)	13 (7)	1 (<1)
CR + PR <sup>e</sup> n (%)	121 (38)	56 (18)	57 (45)	29 (26)	64 (34)	27 (13)
p-value <sup>g</sup>	<0.0001		0.0035		<0.0001	
Median Response Duration						
CR <sup>e</sup>	9.9 mo	NE <sup>h</sup>	9.9 mo	NE	6.3 mo	NA <sup>i</sup>
nCR <sup>e</sup>	11.5 mo	9.2 mo	NE	NE	11.5 mo	9.2 mo
CR + PR <sup>e</sup>	8.0 mo	5.6 mo	8.1 mo	6.2 mo	7.8 mo	4.1 mo

<sup>a</sup> Kaplan-Meier estimate

<sup>b</sup> Hazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than 1 indicates an advantage for bortezomib.


<sup>c</sup> p-value based on stratified log-rank test including randomization stratification factors.

<sup>d</sup> Response population includes patients who had measurable disease at baseline and received at least 1 dose of study drug.

- <sup>e</sup> EBMT criteria<sup>1</sup>: nCR meets all EBMT criteria for CR but has positive IF. Under EBMT criteria, nCR is in the PR category.
- <sup>f</sup> In 2 patients the IF was unknown.
- <sup>g</sup> p-value for Response Rate (CR+PR) from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors.
- <sup>h</sup> Not Estimable
- <sup>i</sup> Not Applicable, no patients in category

There was a statistically significant increase in TTP on the bortezomib arm (see Figure 2.5).

**Figure 2.5: Time to Progression in the Randomized Phase III Multiple Myeloma Trial (Bortezomib vs. Dexamethasone) (N=669)**




There was a statistically significant improvement in both overall and 1-year survival on the bortezomib arm (see Table 2.8, Figure 2.6 and Figure 2.7) as compared to the dexamethasone arm in all patients as well as in patients who had received 1 prior line of therapy. The efficacy endpoints appear durable, based on the median follow-up of 21.9 months (data not shown).

**Table 2.8: Summary of 1-Year and Overall Survival Benefit in the Randomized Phase III Multiple Myeloma Study**


Efficacy Endpoint	All Patients		1 Prior Line of Therapy		> 1 Prior Line of Therapy	
	Bortezomib	Dex	Bortezomib	Dex	Bortezomib	Dex
	N=333	N=336	N=132	N=119	N=200	N=217
<b>1-Year Survival %</b> (95% CI)	80 (74, 85)	66 (59, 72)	89 (82, 95)	72 (62, 83)	73 (64, 82)	62 (53, 71)
p-value	0.0025		0.0082		0.0787	
<b>Overall Survival</b> Events (deaths) n (%)	51 (15)	84 (25)	12 (9)	24 (20)	39 (20)	60 (28)

Efficacy Endpoint	All Patients		1 Prior Line of Therapy		> 1 Prior Line of Therapy	
	Bortezomib	Dex	Bortezomib	Dex	Bortezomib	Dex
Hazard ratio (95% CI)	0.57 (0.40, 0.81)		0.42 (0.21, 0.85)		0.63 (0.42, 0.94)	
p-value	0.0013		0.0130		0.0231	

**Figure 2.6: Overall Survival in the Randomized Phase III Multiple Myeloma Trial (Bortezomib vs. Dexamethasone) (N=669)**



**Figure 2.7: Overall Survival in Patients with One Prior Line of Therapy in the Randomized Phase III Multiple Myeloma Trial (Bortezomib vs. Dexamethasone) (N=251)**



Regardless of  $\beta_2$ -microglobulin levels at baseline, TTP and overall survival were significantly longer on the bortezomib arm ( $\beta_2$ -microglobulin  $\leq 2.5$  mg/L: p=0.0004, p=0.0222, respectively;  $> 2.5$  mg/L: p<0.0001, p=0.0061, respectively). Similarly, the

response rate was significantly higher on the bortezomib arm regardless of screening  $\beta_2$ -microglobulin levels ( $\beta_2$ -microglobulin  $\leq 2.5$  mg/L:  $p=0.0049$ ;  $> 2.5$  mg/L:  $p<0.0001$ ).

### **Randomized, Open-Label Clinical Study in Relapsed Multiple Myeloma comparing Bortezomib Intravenous and Subcutaneous**

An open label, randomized, Phase III non-inferiority study compared the efficacy and safety of the subcutaneous administration of bortezomib versus the intravenous administration. This study included 222 patients with relapsed multiple myeloma, who were randomized in a 2:1 ratio to receive  $1.3 \text{ mg/m}^2$  of bortezomib by either the subcutaneous or intravenous route for 8 cycles. Patients who did not obtain an optimal response (less than Complete Response (CR)) to therapy with bortezomib alone after 4 cycles were allowed to receive dexamethasone 20 mg daily on the day of and after bortezomib administration (82 patients in the subcutaneous treatment group and 39 patients in the intravenous treatment group). Patients with baseline Grade  $\geq 2$  peripheral neuropathy or neuropathic pain, or platelet counts  $<50,000/\mu\text{L}$  were excluded. A total of 218 patients were evaluable for response.

Stratification factors were based on the number of lines of prior therapy the patient had received (1 previous line versus more than 1 line of therapy), and international staging system (ISS) stage (incorporating  $\beta_2$ -microglobulin and albumin levels; Stages I, II, or III).

Baseline patient and disease characteristics are summarized in Table 2.9.

**Table 2.9: Summary of Baseline Patient and Disease Characteristics in the Phase III Trial of Bortezomib Intravenous vs. Subcutaneous**

	<b>IV N=74</b>	<b>SC N=148</b>
<b>Patient Characteristics</b>		
Median age in years (range)	64.5 (38, 86)	64.5 (42, 88)
Gender: male/female	64% / 36%	50% / 50%
Race: caucasian/asian	96% / 4%	97% / 3%
Karnofsky performance status score 70	16%	22%
<b>Disease Characteristics</b>		
Type of myeloma: IgG/IgA/Light chain	72% / 19% / 8%	65% / 26% / 8%
ISS staging <sup>a</sup> I/II/III	27% / 41% / 32%	27% / 41% / 32%
Median $\beta_2$ -microglobulin (mg/L)	4.25	4.20
Median albumin (g/L)	3.60	3.55
Creatinine clearance $\leq 30 \text{ mL/min}$ [n (%)]	2 (3%)	5 (3%)
<b>Median Duration of Multiple Myeloma Since Diagnosis (Years)</b>	2.93	2.68
<b>Number of Prior Therapeutic Lines of Treatment</b>		
1 prior line	65%	62%
> 1 prior line	35%	38%



This study met its primary objective of non-inferiority that single-agent subcutaneous bortezomib retains at least 60% of the overall response rate after 4 cycles relative to single-agent intravenous bortezomib (Table 2.10).

**Table 2.10: Summary of Efficacy Analyses for the Subcutaneous Administration of Bortezomib Compared to Intravenous**

Per-Protocol Population	IV Bortezomib N=68	SC Bortezomib N=132
<b>Response Rate at 4 cycles</b>		
ORR (CR + PR) n (%)	30 (44)	55 (42)
p-value <sup>a</sup>	0.00675	
CR n (%)	6 (9)	8 (6)
PR n (%)	24 (35)	47 (36)
nCR n (%)	3 (4)	8 (6)
<sup>a</sup> P-Value is for the non-inferiority hypothesis that the SC arm retains at least 60% of the response rate in the IV arm		

**Table 2.11: Summary of Secondary Efficacy Analyses for the Subcutaneous (SC) Administration of Bortezomib Compared to Intravenous (IV)**

Per-Protocol Population	IV Bortezomib N=68	SC Bortezomib N=132
<b>Response Rate at 8 cycles</b>		
ORR (CR + PR) n (%)	36 (53)	68 (52)
CR n (%)	9 (13)	14 (11)
PR n (%)	27 (40)	54 (41)
nCR n (%)	6 (9)	12 (9)
<b>TTP, months</b>	9.4	10.4
<b>Progression Free Survival (median), months</b>	8.0	10.2
<b>1-year Overall Survival, %</b>	79.9	71.6

### **Phase II Single-Arm Clinical Study in Relapsed Multiple Myeloma**

#### **Study Demographics and Trial Design:**

The safety and efficacy of intravenous bortezomib were evaluated in an open-label, single-arm, multicentre clinical trial of 202 enrolled patients, 183 of whom had relapsed and refractory myeloma. Patients had received at least 2 prior lines of treatment and were progressing on their most recent treatment. The majority of patients had a very good performance status (only 20%  $\leq$  70 KPS) as patients with low performance status (KPS  $\leq$  60) were excluded from this study. Baseline patient and disease characteristics are summarized in Table 2.12. Type and duration of multiple myeloma are summarized in Table 2.13.

An IV bolus injection of bortezomib 1.3 mg/m<sup>2</sup>/dose was administered twice weekly for 2 weeks (on Days 1, 4, 8 and 11) followed by a 10-day rest period (Days 12 to 21) for a maximum of 8 treatment cycles. The study employed dose modifications for toxicity (see **Product Monograph PART I, DOSAGE AND ADMINISTRATION**). Patients who

experienced a response to bortezomib treatment were allowed to continue bortezomib treatment in an extension study.

**Table 2.12: Summary of Patient Population and Disease Characteristics<sup>†</sup> in the Phase II Multiple Myeloma Trial**

	<b>N=202</b>
<b>Patient Characteristics:</b>	
Median Age in Years (Range)	59 (34, 84)
Gender: Male/Female	60% / 40%
Race: Caucasian/Black/Other	81% / 10% / 8%
Karnofsky Performance Status Score $\leq 70$	20%
Hemoglobin $<100$ g/L	44%
Platelet Count $<75 \times 10^9$ /L	21%
<b>Disease Characteristics:</b>	
Type of myeloma (%): IgG/IgA/Light chain	60% / 24% / 14%
Median $\beta_2$ -microglobulin (mg/L)	3.5
Median Creatinine Clearance (mL/min)	73.9
Abnormal Cytogenetics	35%
Chromosome 13 Deletion	15%
<b>Median Duration of Multiple Myeloma Since Diagnosis in Years</b>	<b>4</b>
<b>Previous Therapy</b>	
Any prior steroids, e.g., dexamethasone, VAD	99%
Any prior alkylating agents, e.g., MP, VBMCP	92%
Any prior anthracyclines, e.g., VAD, mitoxantrone	81%
Any prior thalidomide therapy	83%
Received at least 2 of the above	98%
Received at least 3 of the above	92%
Received all 4 of the above	66%
Any prior stem cell transplant/other high-dose therapy	64%
Prior experimental or other types of therapy	44%
Refractory disease	91%

<sup>†</sup>Based on number of patients with baseline data available

**Table 2.13: Type and Duration of Multiple Myeloma (All Patients Treated, N=202)**

<b>Characteristic</b>	<b>Total (N=202)</b>
<b>Type of myeloma [N, (%)]</b>	
N	202
IgG	122 (60)
Kappa	86 (43)
Lambda	36 (18)
IgA	48 (24)
Kappa	30 (15)
Lambda	17 (8)
Kappa + Lambda	1 (<1)
IgD Lambda	2 (<1)
IgM Lambda	1 (<1)
Light Chain	28 (14)
Unspecified	1 (<1)
<b>Patients with oligo- or non-secretory myeloma</b>	19 (9)
<b>Durie-Salmon stage at diagnosis [N (%)]</b>	
N	185
IA	17 (9)
IIA	33 (18)
IIB	2 (<1)
IIIA	117 (63)
IIIB	16 (9)
<b>Duration since diagnosis (years)</b>	
N	202
Mean ( $\pm$ SD)	4.5 (3.00)
Median	4.0
Minimum, Maximum	1.0, 18.0

**Study Results:**

Response rates to bortezomib alone, median duration of response, time to progression and overall survival are presented in Table 2.14. Overall survival and time to progression were based on 202 patients. However, a total of 188 patients were evaluable for response, as 9 patients with non-measurable disease could not be evaluated for response and 5 patients were excluded because of inadequate prior therapy. Response rates to bortezomib alone were determined by an independent review committee (IRC) based on criteria published by Bladé and others. Complete response required < 5% plasma cells in the marrow, 100% reduction in M protein, and a negative immunofixation test (IF-).

Ninety-eight percent (98%) of patients received a starting dose of 1.3 mg/m<sup>2</sup> with 28% of these receiving this dose throughout the study while 33% of patients who started at a dose of 1.3 mg/m<sup>2</sup> had dose reductions.

The overall response rate was 28% and the median time to response was 38 days. The median survival of all patients enrolled was 17 months. In general, patients who had a confirmed CR received 2 additional cycles of bortezomib treatment beyond confirmation.

Of 202 patients enrolled, 35% were 65 years of age or older. Nineteen percent (19%) of patients aged 65 years or older experienced responses (CR or PR) versus 32% in patients under the age of 65.

By multivariate analysis, the response rate was independent of the number or type of previous therapies. Responses were seen in patients with chromosome 13 abnormalities. There was a decreased likelihood of response in patients > 65 years of age and with > 50% plasma cells in the bone marrow at screening.

**Table 2.14: Summary of Disease Outcomes for Bortezomib Monotherapy in Refractory and Relapsed Multiple Myeloma in a Phase II Clinical Study**

<b>Response Analyses N=188, 1.3 mg/m<sup>2</sup> dose</b>	<b>N (%)</b>	<b>(95% CI)</b>
Overall Response Rate (Bladé) (CR + PR)	52 (27.7)	(21, 35)
Complete Response (CR)	5 (2.7)	(1, 6)
Partial Response (PR)	47 (25)	(19, 32)
Kaplan-Meier Estimated Median Duration of Response (CR + PR)	385 Days	(234, 538)
<b>Median Time to Progression – All Patients (N=202)</b>	<b>213 Days</b>	<b>(154, 297)</b>
<b>Median Overall Survival<sup>‡</sup> - All Patients (N=202)</b>	<b>518 Days</b>	<b>(434, 643)</b>

Note: Responses subsequent to the use of dexamethasone are excluded.

<sup>‡</sup> Bortezomib alone or in combination with dexamethasone

The protocol allowed patients to receive dexamethasone in conjunction with bortezomib if they had a sub-optimal response to bortezomib alone (i.e., 40 mg dexamethasone with each dose of bortezomib administered as 20 mg PO on the day of and 20 mg PO the day after bortezomib administration if the patient had progressive disease after 2 cycles of bortezomib, or progressive or stable disease after 4 cycles of bortezomib). A total of 74 patients were administered dexamethasone in combination with bortezomib and were assessed for response but were excluded in the assessment of disease outcomes for bortezomib monotherapy. Eighteen percent (13/74) of patients had an improved response (MR (11%) or PR (7%)) with combination treatment.

### **A Randomized, Phase II, Dose-Response Study in Relapsed or Refractory Multiple Myeloma**

In a randomized open-label, single-arm, multicentre study in 54 patients with multiple myeloma who had progressed or relapsed on or after front-line therapy, 28 patients received 1.0 mg/m<sup>2</sup>/dose and 26 patients received 1.3 mg/m<sup>2</sup>/dose twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 to 21). The majority of these patients were not refractory to treatment and had received less than 2 prior lines of therapy. A single complete response was seen at each dose with an additional 2 near complete responses (immunofixation positive) in the 1.0 mg/m<sup>2</sup> dose group. Based on an update of secondary efficacy endpoints, the median time to progression (TTP) for the 1.0 mg/m<sup>2</sup> dose was 127 days (4.2 months), while the median TTP for the 1.3 mg/m<sup>2</sup> dose was 357 days (11.7 months). The median survival for the 1.0 mg/m<sup>2</sup> dose group was 813 days (26.7 months), while the median survival for the 1.3 mg/m<sup>2</sup> dose group has not yet been reached.

## **A Phase II Open-Label Extension Study in Multiple Myeloma**

Patients from the two Phase II studies who in the investigators' opinion would experience additional clinical benefit were allowed to receive intravenous bortezomib beyond 8 cycles on an extension study. Sixty-three (63) patients from the Phase II multiple myeloma studies were enrolled and received a median of 7 additional cycles of bortezomib therapy for a total median of 14 cycles (range 7 to 32). The overall median dosing intensity was the same in both the parent protocol and extension study. Sixty-seven percent (67%) of patients initiated the extension study at the same or higher dose intensity at which they completed the parent protocol, and 89% of patients maintained the standard 3-week dosing schedule during the extension study. No new cumulative or new long-term toxicities were observed with prolonged bortezomib treatment, although the incidence of some adverse events was higher in this extension study than in the parent studies (see *Product Monograph PART I, ADVERSE REACTIONS*).

## **A Phase II Single-Arm Clinical Study in Mantle Cell Lymphoma**

The safety and efficacy of bortezomib in relapsed or refractory mantle cell lymphoma were evaluated in an open-label, single-arm, multicentre study of 155 patients with progressive disease who had received at least 1 prior therapy. The median age of the patients was 65 years (42, 89), 81% were male, and 92% were Caucasian. Of the total, 75% had one or more extra-nodal sites of disease, and 77% were stage 4. Data on B symptoms were not collected for these patients. In 91% of the patients, prior therapy included all of the following: an anthracycline or mitoxantrone, cyclophosphamide, and rituximab. A total of thirty seven percent (37%) of patients were refractory to their last prior therapy. Baseline patient and disease characteristics are summarized in Table 2.15.

**Table 2.15: Summary of Baseline Patient and Disease Characteristics in the Phase II Mantle Cell Lymphoma Study**

	<b>N=155</b>
<b>Patient Characteristics</b>	
Median Age in years (range)	65 (42, 89)
Gender: male/female	81% / 19%
Race: Caucasian/black/other	92% / 4% / 5%
Karnofsky Performance Status, <90	29%
<b>Disease Characteristics</b>	
Median Time Since Initial Diagnosis to First Dose (years)	2.3
Diagnosed <3 years Prior to First Dose	66%
MCL Stage III or IV at Screening	92%
International Prognostic Index $\geq 3$	44%
Elevated Lactate Dehydrogenase	36%
$\geq 2$ Involved Extranodal Sites	34%
Histopathology: Diffuse Growth Pattern	79%
Bone Marrow Positive for MCL	55%
<b>Number of Prior Lines of Therapy</b>	
1	54%
2	42%
3	4%
<b>Received Prior Regimen Containing</b>	

	N=155
Anthracycline/Mitoxantrone	98%
Alkylating Agents	97%
Rituximab	96%
Received at Least 2 of the Above 3	100%
Received All of the Above 3	91%
<b>Received Prior High-Intensity Therapy</b>	37%
Received SCT or hyper-CVAD with/without rituximab	32%
Received Prior High-Intensity Therapy as Last Prior Regimen	30%
Received SCT or hyper-CVAD with/without rituximab as Last Prior Regimen	26%

SCT= stem cell transplant, hyper-CVAD=hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine

Intravenous bortezomib was administered at the recommended dose of 1.3 mg/m<sup>2</sup> twice weekly on Days 1, 4, 8 and 11 of a 21-day cycle. The median number of cycles administered across all patients was 4 (range 1-17); and 8 in responding patients. The mean number of treated cycles across all patients was 5.7. The median time to response was 40 days (range 31 to 204 days). Response rates to bortezomib are described in Table 2.16. Bortezomib demonstrated similar efficacy regardless of the number of prior lines of therapy, with the exception that duration of response was longer in patients who had received only one prior line. Response rates to bortezomib were determined according to the International Workshop Criteria (IWRC) based on independent radiologic review of CT scans.

**Table 2.16: Summary of Disease Outcomes in a Phase II Mantle Cell Lymphoma Study**

	All Patients (N=141)		1 Prior Line of Therapy (N=77)		> 1 Prior Line of Therapy (N=64)	
<sup>†</sup> Response Analyses	N (%)	95% CI	N (%)	95% CI	N (%)	95% CI
CR + CRu + PR	47 (33)	(26, 42)	23 (30)	(20, 41)	24 (38)	(26, 50)
CR + CRu	11 (8)	(4, 14)	5 (6)	(2, 15)	6 (9)	(4, 19)
CR	9 (6)	(3, 12)	5 (6)	(2, 15)	4 (6)	(2, 15)
CRu	2 (1)	(0, 5)	0		2 (3)	(0, 11)
PR	36 (26)	(19, 34)	18 (23)	(14, 34)	18 (28)	(18, 41)
Time to Event Analyses	No. of Events (%)	Median (95% CI)	No. of Events (%)	Median (95% CI)	No. of Events (%)	Median (95% CI)
Kaplan-Meier Estimated Duration of Response						
CR + CRu + PR (N=47)	20 (43)	9.2 months (4.9, 13.5)	11 (48)	9.4 months (5.4, 13.4)	9 (38)	6.1 months (4.2, NE)
CR + CRu (N= 11)	3 (27)	13.5 months (13.5, NE)	1 (20)	13.4 months (NE, NE)	2 (33)	NE (4.7, NE)
Kaplan-Meier Estimated Time to Progression (N=155)	75 (48)	6.2 months (4.0, 6.9)	43 (51)	6.5 months (3.8, 7.2)	32 (45)	5.4 months (3.2, 7.3)
<sup>‡</sup> Kaplan-Meier Estimated Treatment-free Interval, CR + CRu (N=11)	13.8 months	(13.4, NE)				
Median Time to Next Treatment CR + CRu + PR	12.7	(9.33, NE)				

	All Patients (N=141)	1 Prior Line of Therapy (N=77)	> 1 Prior Line of Therapy (N=64)
(N=45)	months		
CR + CRu (N=11)	19.4	(17.8, NE)	
	months		


NE=Not Estimable; CR=Complete Response; CRu=Complete Response Unconfirmed; PR=Partial Response

† Based on International Response Workshop Criteria (IRWC)


‡ Additional analyses

The Kaplan-Meier curves for the duration of response and the time to progression are presented in Figures (2.8 and 2.9).

**Figure 2.8: Duration of Response in the Phase II Mantle Cell Lymphoma Study (N=47)**




**Figure 2.9: Time to Progression in the Phase II Mantle Cell Lymphoma Study (N=155)**



With a median duration of follow up of more than 26 months for surviving patients, the median overall survival was 23.6 months with the median survival for responders

(CR/CRu/PR) being 35.6 months. The Kaplan-Meier estimate of 1-year survival was 93.5% in responders (CR, CRu, PR). The Kaplan-Meier curve for overall survival of all treated patients is provided in Figure 2.10.

**Figure 2.10: Overall Survival in the Phase II Mantle Cell Lymphoma Study (N=155)**



The results of the above Phase II study are supported by a second multicentre study sponsored by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). In this single arm Phase II study of 29 patients, which included 15 patients who relapsed after 1 or 2 prior chemotherapy regimens, single agent bortezomib provided durable responses (10.3 months) for patients, with relapsed MCL achieving a response rate of 47%. The results of this study along with the results of the previous Phase II MCL study, provide support that bortezomib provides clinical benefit in the form of durable responses. The clinical benefit is manifested by delaying the need for alternate cytotoxic chemotherapy and delay the onset of symptoms typically associated with progressive disease.

### **Randomized Phase III Clinical Study in Patients with Previously Untreated Mantle Cell Lymphoma**

A randomized, open-label, Phase 3 study (LYM-3002) was conducted in 487 adult patients with previously untreated mantle cell lymphoma (Stage II, III or IV) who were unsuitable (ineligible, or not considered for other non-medical reason) for bone marrow transplant. The study was conducted to determine whether bortezomib administered in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP) resulted in improvement in progression free survival (PFS) when compared to the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This clinical study utilized independent pathology confirmation and independent radiologic response assessment.



Patients in the VcR-CAP treatment arm received bortezomib (1.3 mg/m<sup>2</sup>) administered intravenously on days 1, 4, 8, and 11 (rest period days 12-21); rituximab (375 mg/m<sup>2</sup>) on Day 1; cyclophosphamide (750 mg/m<sup>2</sup>) on Day 1; doxorubicin (50 mg/m<sup>2</sup>) on Day 1; and prednisone (100 mg/m<sup>2</sup>) on Day 1 through Day 5 of the 21-day treatment cycle. For patients with a response first documented at cycle 6, two additional treatment cycles were given.

Patient and disease characteristics are shown in Table 2.17.

<b>Patient Characteristics</b>	<b>VcR-CAP N=243</b>	<b>R-CHOP N=244</b>
Median age in years (range)	65 (38; 86)	66 (34; 82)
Gender: male/female	73%/27%	75%/25%
Race: caucasian/asian	62%/36%	71%/28%
<b>Disease Characteristics</b>		
Bone marrow aspirate positive: yes/no	56%/39%	58%/40%
Bone marrow biopsy positive: yes/no	62%/35%	64%/35%
Disease stage: II/III/IV	5%/20%/75%	7%/17%/76%
International Prognostic Index (IPI) score:		
Low-intermediate/high-intermediate/high	31%/35%/19%	29%/36%/19%

The median number of cycles received by patients in both treatment arms was 6 with 17% of patients in the R-CHOP group and 14% of subjects in the VcR-CAP group receiving 2 additional cycles. The majority of the patients in both groups received 6 or more cycles, 83% in the RCHOP group and 84% in the VcR-CAP group.

The primary efficacy endpoint was progression-free survival based on Independent Review Committee (IRC) assessment. Secondary endpoints included overall response rate (CR/CRu/PR) and complete response (CR/CRu) rate, response duration, and overall survival (OS). The response criteria used to assess efficacy were based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (IWRC).

Efficacy results at a median follow-up of 40 months are presented in Table 2.18. The combination of VcR-CAP resulted in a statistically significant prolongation of PFS compared with R-CHOP.

**Table 2.18: Summary of Efficacy Outcomes in a Phase 3 Mantle Cell Lymphoma Study in Previously Untreated Patients (LYM-3002)**

Efficacy endpoint	VcR-CAP	R-CHOP	
n: ITT patients	243	244	
<b>Progression free survival (IRC)<sup>a</sup></b>			
Events n (%)	133 (54.7)	165 (67.6)	HR <sup>c</sup> (95% CI)=0.63 (0.50;0.79)
Median <sup>b</sup> (95% CI) (months)	24.7 (19.8; 31.8)	14.4 (12; 16.9)	p-value <sup>d</sup> < 0.001
<b>Response Rate</b>			
n: response-evaluable patients	229	228	
Overall complete response (CR+CRu) <sup>e</sup> n(%)	122 (53.3)	95(41.7)	
Overall radiological response (CR+CRu+PR) <sup>f</sup> n(%)	211 (92.1)	204 (89.5)	
<b>Response Duration</b>			
<i>Duration of complete response (CR+CRu)<sup>g</sup></i>			
n: response-evaluable patients	122	95	
Median <sup>b</sup> (95% CI) (months)	42.1 (30.7; 49.1)	18.0 (14.0; 23.4)	
<i>Duration of Response (CR+CRu+PR)<sup>h</sup></i>			
n: response-evaluable subjects	211	204	
Median <sup>b</sup> (95% CI) (months)	36.5 (26.7; 46.7)	15.1 (12.5; 17.0)	

<sup>a</sup> Based on Independent Review Committee (IRC) assessment (radiological data only).

<sup>b</sup> Based on Kaplan-Meier product limit estimates.

<sup>c</sup> Hazard ratio estimate is based on a Cox's model stratified by IPI risk and stage of disease. A hazard ratio < 1 indicates an advantage for VcR-CAP.

<sup>d</sup> Based on Log rank test stratified with IPI risk and stage of disease.

<sup>e</sup> Include all CR + CRu, by IRC, with verification by bone marrow and LDH.


<sup>f</sup> Include all radiological CR+CRu+PR by IRC without verification by bone marrow and LDH.

<sup>g</sup> Calculated from first date of complete response (CR+CRu by IRC, bone marrow and LDH ) to date of PD or death due to PD.

<sup>h</sup> Calculated from first date of response (include all radiological CR+CRu+PR by IRC) to date of PD or death due to PD.

CR=Complete Response; CRu=Complete response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=hazard ratio; ITT=intent to treat

**Figure 2.11. Kaplan-Meier plot of progression-Free survival: per Independent Review Committee; ITT-analysis set.**



Key: R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone;  
VcR-CAP = bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone.

There was a trend towards prolonged overall survival favoring the VcR-CAP group with a median duration of follow-up of 40 months. Median OS (56.3 months in the R-CHOP group, and not reached in the VcR CAP group) favored the VcR-CAP group, (estimated HR[95%CI]=0.80[0.59, 1.10]; p=0.173). The overall survival data is not yet mature and will be confounded by post-progression therapy.

## **DETAILED PHARMACOLOGY**

### **Non-Clinical Pharmacology**

Bortezomib-mediated proteasome inhibition affects cancer cells in a number of ways, including, but not limited to, altering regulatory proteins, which control cell cycle progression and Nuclear Factor kappa B (NF-κB) activation. Inhibition of the proteasome results in cell cycle arrest and apoptosis. NF-κB is a transcription factor whose activation is required for many aspects of tumorigenesis, including cell growth and survival, angiogenesis, cell:cell interactions, and metastasis. *In vitro*, bortezomib affects the ability of myeloma cells to interact with the bone marrow environment.

Proteasome activity in peripheral blood cells and/or packed whole blood was measured by fluorogenic kinetic assays for both the chymotryptic and tryptic activities of the proteasome.

In *in vivo* studies conducted in Lewis Lung, human prostate carcinoma, and multiple myeloma plasmacytoma xenografts, bortezomib dose-dependently reduced tumour volume when administered intravenously, twice weekly, as a single agent at doses varying between 0.9 and 3.0 mg/m<sup>2</sup>.

### **Non-Clinical Safety Pharmacology**

In monkeys, administration of single IV dosages of  $\geq 3.0$  mg/m<sup>2</sup> (approximately twice the recommended clinical dose) resulted in altered temperature control and heart rate elevations, followed by profound progressive hypotension, bradycardia, and death 12-14 hours post-dose. Doses  $\geq 1.2$  mg/m<sup>2</sup> induced dose-proportional changes in cardiac parameters (Table 2.19).

In conscious telemetered Beagle dogs, a single intravenous administration of bortezomib at 5.0 or 6.0 mg/m<sup>2</sup> induced a decline in blood pressure, an increase in heart rate, and a decrease in cardiac contractility and left ventricular end diastolic pressure. Twenty-four hours after bortezomib treatment, animals responded to acute, intravenous, pharmacologic interventions using dopamine and/or phenylephrine, with amelioration of the negative pressor and contractility effects (Table 2.19).

In conscious telemetered Beagle dogs, a single intravenous administration of bortezomib at 1.3 mg/m<sup>2</sup> had no effect on arterial blood pressure, heart rate, ECG intervals or respiratory rate. At 4.0 mg/m<sup>2</sup>, loose feces, bloated abdomens, vomiting, laboured breathing, slow capillary refill time, cold extremities and gums, hind limb tremors, lip-licking, salivation and subdued behaviour were observed which resulted in the sacrifice of 4 out of 6 dogs. When compared with pre-dose baseline values, QTc intervals increased (Table 2.19).

**Table 2.19: Summary of Safety Pharmacology Studies**

Study Title	Species/ Number of Animals	Dosage/Route	Principal Findings
Cardiovascular Safety Pharmacology Study of Bortezomib in Telemetered Monkeys <sup>†</sup>	Cynomolgus monkeys, 1M/group (telemetered animals)	Single dose IV at 1.2, 2.4, 3.0, and 3.6 mg/m <sup>2</sup>	Mortality at doses ≥3.0 mg/m <sup>2</sup> . Rapid breathing, soft feces/diarrhea, tremors, and drooling at 3.6 mg/m <sup>2</sup> , hypoactivity at dosages ≥3.0 mg/m <sup>2</sup> , emesis at dosages ≥2.4 mg/m <sup>2</sup> . ↑HR, BT, severe ↓BP, death 13 to 14 hours post-dose at dosages ≥3.0 mg/m <sup>2</sup> . 2.4 mg/m <sup>2</sup> : ↑HR, BT, ↓BP for 12-24 hours, cyclicity affected for 5 days. 1.2 mg/m <sup>2</sup> : ↑HR, BT, BP, cyclicity affected for 1 day
Investigative Cardiovascular Safety Study Following Intravenous Administration of Bortezomib in Telemetered Male Beagle Dogs <sup>†</sup>	Beagle dogs, 4M/group in definitive study, 5M in pilot study (telemetered animals)	Single dose IV at 5 mg/m <sup>2</sup> (pilot study) or 6 mg/m <sup>2</sup> (definitive study)	↑HR, ↓BP, ↓contractility, ↓left ventricular end diastolic pressures within 24 hours post-dose. ECG changes: ↑PR, QRS, QT, QTc intervals 12-22 hours post-dose. Animals' responses to the combined dopamine and phenylephrine challenges pre- and post-dosing were unchanged. In addition, animals responded to acute dopamine and/or phenylephrine, with amelioration of the negative pressor and contractility effects.
Cardiovascular Effects of Bortezomib in Conscious, Telemetered Beagle Dogs	Beagle dogs, 4M/group (telemetered animals)	Single dose IV at 1.3 mg/m <sup>2</sup> and 4.0 mg/m <sup>2</sup>	Mortality at the 4.0 mg/m <sup>2</sup> dose. 4.0 mg/m <sup>2</sup> : ↑HR, ↓BP, ↓RR, PR, and QT intervals, and sustained prolongation of QTc intervals. 1.3 mg/m <sup>2</sup> : no adverse clinical signs and no consistent effect on hemodynamic parameters.

<sup>†</sup> Non-GLP Study

### **Non-Clinical Pharmacokinetics**

The kinetic and metabolic profile of bortezomib is similar in rats and monkeys. In distribution studies in rats and monkeys, bortezomib is rapidly distributed after IV administration. The highest tissue concentrations of radioactivity were initially in organs of excretion and metabolism (i.e. kidney and liver), in some tissues related to endocrine (i.e. adrenal and pituitary gland), and secretory functions (i.e. salivary gland) and in regions of rapidly dividing cells (i.e. mucosal lining of the alimentary canal, bone marrow, and spleen). Radioactivity was not detectable in the brain, spinal cord and

various regions of the eye and optic nerve. Radioactivity was detected in pituitary and choroid plexus, suggesting that the blood-brain barrier does not protect against entry into at least these parts of the CNS.

In the majority of the tissues investigated, the highest concentration of radioactivity was observed at 1 h after dosing. In a few tissues (like lymph nodes, spleen and thymus), the highest concentration occurred at a later observed time point (24 to 144 hours after dosing). Studies in a mouse model of efficacy also indicated uptake of [ $^{14}\text{C}$ ]-bortezomib into tumours.

Kinetic analysis of repeated dose studies using the clinical dosing regimen of IV dosing twice weekly for 2 weeks followed by one week rest in the monkey shows an increase in the terminal elimination half-life and a decrease in clearance with repeated dosing. The area under the plasma concentration versus time curve (0 to 24 h) approximately doubled from the first to the second cycle with no further increases in AUC at cycle 13 (Table 2.20).

**Table 2.20: Mean (SD) Area Under the Plasma Concentration Versus Time Curve for Bortezomib in Monkeys Following 13 Cycles of Dosing Twice Weekly, 10 Days Off**

		0.6 mg/m <sup>2</sup>				0.9 mg/m <sup>2</sup>				1.2 mg/m <sup>2</sup>			
Week	Cycle	T <sub>1/2</sub> -z (hr)	V <sub>z</sub> (L/kg)	Cl (L/hr/kg)	AUC <sub>0-24</sub> (hr*ng/ mL)	T <sub>1/2</sub> -z (hr)	V <sub>z</sub> (L/kg)	Cl (L/hr/kg )	AUC <sub>0-24</sub> (hr*ng/ mL)	T <sub>1/2</sub> -z (hr)	V <sub>z</sub> (L/kg)	Cl (L/hr/kg )	AUC <sub>0-24</sub> (hr*ng/ mL)
1	1	2.65 -0.236	13.7 -3.69	3.57 -0.829	12.3 (2.69)	9.91 (3.86)	22.2 (4.88)	1.9 (1.09)	34.6 (10.4)	7.78 (3.16)	17.6 (5.59)	1.74 (0.522)	51.3 -10.6
5	2	12.9 (2.92)	15.1 -3.27	0.841 -0.19	45.1 (7.73)	12.4 (3.64)	11.7 -3.22	0.676 (0.191)	82.9 (15.2)	9.68 (2.59)	10.5 (2.72)	0.778 (0.214)	111 (29.5)
37	13	47.9 (43.9)	26 (12.8)	0.644 -0.479	38.5 (5.56)	130 (77.2)	49.5 (10.2)	0.309 (0.109)	58.4 (13.8)	95.3 (28.4)	53 (18.9)	0.395 (0.129)	72.8 (13.8)
38	13	55 (30.8)	26.4 (5.68)	0.429 (0.207)	45.4 (10.9)	46.7 (12)	26.5 (9.42)	0.388 -0.054	74.9 (17.8)	53.4 (11.7)	31.7 (6.75)	0.423 (0.102)	92.3 (14.3)

The binding of bortezomib to rat, cynomolgus monkey and human plasma proteins was similar across the three species. Over a bortezomib concentration range of 10 to 1000 ng/mL, the *in vitro* protein binding averaged 84.9% in rat plasma, 72.4% in cynomolgus monkey plasma and 82.9% in human plasma. The percent of bortezomib bound to plasma proteins was not concentration dependent.

*In vitro* and *in vivo* studies indicated that bortezomib is extensively metabolized in rats, monkeys and humans, producing greater than 30 metabolites through P450 dependent and independent pathways. Bortezomib has not been shown to be metabolized via phase II pathways, e.g., glucuronidation and sulfation.

Bortezomib has been shown to be a poor inhibitor of human recombinant expressed CYP isozymes, with IC<sub>50</sub> ≥ 30 μM or 11.5 μg/mL for CYP 1A2, 2C9, 2D6 and 3A4, and IC<sub>50</sub> ≥ 18 μM or 6.9 μg/mL for 2C19. Bortezomib did not induce the activities of CYP 3A4

and 1A2 in primary cultured human hepatocytes. In addition, bortezomib does not appear to be a substrate for p-glycoprotein (Pgp) and several other drug efflux pumps.

Biliary excretion is the primary route of elimination of [ $^{14}\text{C}$ ]-bortezomib-derived radioactivity in rats. In intact rats, 38.6% of the administered radioactivity was recovered in feces, 21.1% was recovered in urine, and 6.12% was recovered in expired air in 72 hours.

In the monkey, [ $^{14}\text{C}$ ]-bortezomib-derived radioactivity was excreted in both the urine and bile. Within the first 24 hours, 30 to 40% of the total recovered radioactivity was excreted via urine or feces. The remaining 60 to 70% of the recovered radioactivity was eliminated slowly during the next 120 hours.

Transfer of bortezomib across the placenta and secretion in milk have not been determined.

## **Clinical Pharmacology**

### **Pharmacodynamics:**

The level of proteasome inhibition obtained at the therapeutic dose of 1.3 mg/m<sup>2</sup> appears consistent across different studies. Table 2.21 summarizes data from a Phase I study relative to a range of doses (1.2 to 1.38 mg/m<sup>2</sup>) similar to the dose used in Phase II studies (1.3 mg/m<sup>2</sup>), demonstrating a similar mean maximum inhibition and an equally similar inter-individual variability.

**Table 2.21: Comparative Values of Proteasome Inhibition Level Across Studies<sup>‡</sup>**

Study/Dose (mg/m <sup>2</sup> )	Cycle 1, Day 1, 1 Hour Post-Dose		
	N	Mean Percent (%) Inhibition of 20S Proteasome Activity	Range (%)
Phase I Study LCC9834/00-31 (1.2-1.38)	18	63	36-92
Phase II Study M34100-025 (1.3)	141	61	14-97
Phase II Study M34100-024 (1.3)	11	71	51-89

<sup>‡</sup> Based on whole blood assay

### **Pharmacokinetics:**

A Phase I study was conducted in relapsed multiple myeloma patients to characterize the pharmacokinetics of bortezomib following single and multiple doses. Following intravenous bolus administration of 1.0 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup> doses to 24 patients (n = 12 per each dose level), the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/mL, respectively. In subsequent doses administered twice weekly, mean maximum observed plasma concentrations ranged from 67 to 106 ng/mL for the 1.0 mg/m<sup>2</sup> dose and 89 to 120 ng/mL for the 1.3 mg/m<sup>2</sup> dose. The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours for the 1.0 mg/m<sup>2</sup> dose, and 49 to 109 hours for the 1.3 mg/m<sup>2</sup> dose. Bortezomib is eliminated more rapidly following the first dose compared to subsequent doses. Mean total body clearances were

102 and 112 L/h following the first dose for doses of 1.0 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup>, respectively, and ranged from 15 to 32 L/h following subsequent doses for doses of 1.0 mg/m<sup>2</sup> and 1.3 mg/m<sup>2</sup>, respectively.

## TOXICOLOGY

In animal studies at a dose and schedule similar to that recommended for patients (twice weekly dosing for 2 weeks followed by 1 week rest), toxicities observed included severe anemia and thrombocytopenia, gastrointestinal, neurological, testicular, ovarian and lymphoid system toxicities. Neurotoxic effects of bortezomib in animal studies included axonal swelling and degeneration in peripheral sensory nerves, dorsal spinal roots, and tracts of the spinal cord. Additionally, in the monkey, multifocal hemorrhage and necrosis in the brain, eye, and heart were observed, these effects considered related to anemia/thrombocytopenia-induced ischemia.

The range between lethal and non-lethal doses after both acute and repeated dose administration is narrow in all species evaluated (mice, rat, monkey and dog). In repeated dose studies, bortezomib lethality occurred after multiple cycles (twice weekly for 2 weeks, 10 days off) at 0.9 mg/m<sup>2</sup> in both rats and monkeys, i.e. lower than proposed clinical dose with hematopoietic, gastrointestinal and lymphoid system lesions considered to be contributing factors to the debilitated state and early death and lethality.

Table 2.22 summarizes some single-dose and repeat-dose toxicity studies conducted in rats and monkeys.

**Table 2.22: Summary of Single-Dose and Repeat-Dose Toxicology Studies**

Study Title	Species/Number of Animals	Dosage/Route	Principal Findings
<b>Single-Dose</b>			
Single Dose Intravenous Toxicity and Toxicokinetic Study with Bortezomib in Rats <sup>†</sup>	Sprague-Dawley rats 5/sex/group main study animals and 6-9/sex/group TK	Single dose IV at 0, 0.18, 0.6, and 1.8 mg/m <sup>2</sup>	Mortality at 1.8 mg/m <sup>2</sup> , 2/5 F on Day 2. No abnormal clinical signs. ↑WBC, ↓erythroid parameters, platelets at 1.8 mg/m <sup>2</sup> . ↑BUN/creat., AST/ALT in individuals at 1.8 mg/m <sup>2</sup> . No test article-related macroscopic or microscopic findings. NOAEL and MTD were 0.6 mg/m <sup>2</sup> .
<b>Repeat-Dose</b>			
26-Week Intravenous Injection Toxicity Study of Bortezomib in the Albino Rat <sup>†</sup>	Sprague-Dawley rats 10/sex/group main study and 10/sex/group recovery animals and 12/sex/group TK/PD	Twice weekly IV for 2 consecutive weeks with 1 week off (1 cycle). 26 weeks equals 9 cycles. 0, 0.3, 0.6, and 1.2/0.9 mg/m <sup>2</sup> . 8-Week recovery period.	Mortality at 1.2/0.9 mg/m <sup>2</sup> . ↓Body weights in males at dosages ≥0.6 mg/m <sup>2</sup> . ↓Food consumption at 1.2/0.9 mg/m <sup>2</sup> . ↓Platelet counts and erythrocytic parameters and cholesterol levels at all dosages and potassium at dosage ≥0.6 mg/m <sup>2</sup> and total protein, albumin and globulin at 1.2/0.9 mg/m <sup>2</sup> . ↑WBC, fibrinogen, blood glucose and phosphorus at all dosages. ↑Liver weights at all dosages and kidneys (females only) at dosages ≥0.6 mg/m <sup>2</sup> . ↓Thymus and epididymal weights at 1.2/0.9 mg/m <sup>2</sup> . Microscopic changes to liver, GI and salivary gland at all dosages. Microscopic changes to kidneys, lymphoid organs/tissues, spleen, nasolacrimal ducts, fat (males only) and ovaries at ≥0.6 mg/m <sup>2</sup> . Anterior and/or posterior uveitis (males only) and testicular changes at 1.2/0.9 mg/m <sup>2</sup> . Hypocellularity/necrosis of bone marrow at dosages ≥0.6 mg/m <sup>2</sup> . Reversibility observed except for platelet counts, glucose levels, liver and spleen microscopic changes although trend noted. NOAEL was not determined. MTD was 0.6 mg/m <sup>2</sup> .
4-Week IV Toxicity Study with Bortezomib in Cynomolgus Monkeys <sup>†</sup>	Cynomolgus monkeys 3/sex/group main study animals and 2/sex/group recovery animals	Twice-weekly IV for 4 weeks at 0, 0.54, 0.8, and 1.2 mg/m <sup>2</sup> /dose with a 2-week recovery	Mortality at 1.2 mg/m <sup>2</sup> in 1M on Day 26. ↑Monocytes, ↓lymphocytes at dosages ≥0.8 mg/m <sup>2</sup> . ↓Erythroid parameters in males at 1.2 mg/m <sup>2</sup> . ↑Fibrinogen, ↓total protein at 1.2 mg/m <sup>2</sup> . Minimal to mild axonal degeneration, slight lymphocytic depletion of the spleen and mild tubular nephrosis and slight glomeruli changes at



			1.2 mg/m <sup>2</sup> . Trend towards recovery was noted except for ↓lymphocyte count in one male and axonal degeneration in one female at 1.2 mg/m <sup>2</sup> . NOAEL was 0.54 mg/m <sup>2</sup> . MTD was 0.80 mg/m <sup>2</sup> /dose.
A 38-Week (13-Cycles) IV Injection Toxicity Study of Bortezomib in the Cynomolgus Monkey <sup>†</sup>	Cynomolgus monkeys 3/sex/group main study animals and 3/controls/sex and 1F at 0.6 mg/m <sup>2</sup> and 3M and 2F at 1.2 mg/m <sup>2</sup> assigned to recovery evaluation.	Twice-weekly IV with one week off (3 week cycle) for 38 weeks at 0, 0.6, 0.9, and 1.2 mg/m <sup>2</sup> with an 8-week recovery	Mortality at dosages ≥0.9 mg/m <sup>2</sup> . 1/6 M and 2/6F at 1.2 mg/m <sup>2</sup> and 1/3F at 0.9 mg/m <sup>2</sup> . Cause of deteriorating condition was GI intolerance in 1 animal and severe anemia and thrombocytopenia in 3 animals. ↓Erythrocyte, leukocyte and platelet parameters at all dosages with onset between Day 72 and 170. ↑Fibrinogen values at all dosages starting on Day 170. Bone marrow changes at all dosages generally reflective of hematological changes. ↑Liver and kidney weights at all dosages. Microscopic findings in bone marrow, lymphoid organ/tissues at all dosage levels. Peripheral nervous system, kidney, intestinal tract and liver/gallbladder findings at dosages ≥0.9 mg/m <sup>2</sup> . Recovery: Bone marrow, mandibular lymph nodes and spleen demonstrated reversible hyperplastic response. Kidney, thymus and PNS showed incomplete reversibility. NOAEL was not determined. MTD was 0.6 mg/m <sup>2</sup> .

<sup>†</sup> GLP Study  
TK=toxicokinetic  
PD=pharmacodynamic

## **Mutagenicity**

As summarized in Table 2.23, bortezomib showed clastogenic activity (structural chromosomal aberrations) in the *in vitro* chromosomal aberration assay using Chinese hamster ovary cells. Bortezomib was not genotoxic when tested in the *in vitro* mutagenicity assay (Ames test) and *in vivo* micronucleus assay in mice.

**Table 2.23: Summary of Mutagenicity Studies**

Study Title	Species/Number of Animals	Dosage/Route	Principal Findings
<i>In vitro</i> Mammalian Chromosome Aberration Test in Chinese Hamster Ovary Cells <sup>†</sup>	Chinese Hamster Ovary cell line	≤ 200 µg/mL	Bortezomib was positive for induction of structural chromosome aberrations and negative for induction of numerical chromosome aberrations in CHO cells.
Mammalian Erythrocyte Micronucleus Test in Mice <sup>†</sup>	ICR mice 5/sex/group	Single dose IV at 0, 0.75, 1.50, and 3.00 mg/m <sup>2</sup>	Bortezomib showed no clastogenic potential under the test conditions.
Bacterial Reverse Mutagenicity Assay <sup>†</sup>	<i>Salmonella typhimurium</i> and <i>Escherichia coli</i>	≤ 5000 µg/plate	Bortezomib showed no mutagenic potential under the test conditions.

<sup>†</sup> GLP study

## **Reproductive and Developmental Toxicity**

There are no dedicated studies to assess effects on fertility but with degenerative effects in the ovary at ≥ 0.3 mg/m<sup>2</sup> and degenerative changes in the testes at 0.9/1.2 mg/m<sup>2</sup> in the 6-month rat toxicity study, reduced fertility is expected. Due to maternal toxicity, embryo fetal development studies were conducted at sub-therapeutic doses; however, bortezomib was administered daily (Table 2.24).

**Table 2.24: Summary of Embryo Fetal Development Studies**

Study Title	Species/Number of Animals	Dosage/Route	Principal Findings
An Intravenous Injection Teratology Study of Bortezomib in the Sprague-Dawley Rat <sup>†</sup>	Time-mated Sprague-Dawley Rats/22 females/group	Daily IV from gestation day 6 to 17 inclusive at 0, 0.15, 0.30, and 0.45 mg/m <sup>2</sup> /day.	↓Transitory body weight at 0.45 mg/m <sup>2</sup> . ↓Food consumption at 0.45 mg/m <sup>2</sup> . No selective embryo-lethal or fetal-toxic effects were observed at dosages ≤0.45 mg/m <sup>2</sup> .
An Intravenous Injection Teratology Study of Bortezomib in the New Zealand White Rabbit <sup>†</sup>	Time-mated New Zealand White rabbits/22 females/group	Daily IV administration from gestation Day 7 to 19 inclusive at 0, 0.11, 0.28, and 0.55 mg/m <sup>2</sup> /day.	Mortality in one female at 0.55 mg/m <sup>2</sup> and 4 does showed signs of abortion and related clinical signs ↓Weight gain and food consumption at 0.55 mg/m <sup>2</sup> ↓Numbers of live fetuses and fetal weight at 0.55 mg/m <sup>2</sup> No selective embryo-lethal or fetal-toxic effects were observed at dosages

Study Title	Species/Number of Animals	Dosage/Route	Principal Findings
			$\leq 0.28 \text{ mg/m}^2$ . NOAEL and MTD were $0.28 \text{ mg/m}^2$
† GLP Study			

## REFERENCES

1. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, *et al.* Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. *British Journal of Haematology* 1998; 102 (5): 1115-23.
2. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, *et al.* Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. *Cancer* 2005; 104(10): 2141-8.
3. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, *et al.* Bortezomib in recurrent and/or refractory multiple myeloma. *Cancer* 2005; 103(6): 1195- 1200.
4. Jagannath S, Barlogie B, Berenson J, *et al.* A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. *Br J Haematol* 2004; 127: 165-72.
5. Lonial S, Waller EK, Richardson PG, Jagannath S, Orłowski RZ, Giver CR, *et al.* Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. *Blood* 2005; 106(12): 3777-84.
6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, *et al.* A phase 2 study of bortezomib in relapsed, refractory myeloma. *The New England Journal of Medicine* 2003; 348: 2609-17.
7. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, *et al.* Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. *Blood* 2005; 106(9): 2977-81.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, *et al.* Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2005; 352: 2487-98.
9. San Miguel JF, Schlag R, Khuageva NK *et al.* Bortezomib plus melphalan and prednisone for Initial Treatment of multiple myeloma. *N Engl J Med* 2008; 359: 906-17.
10. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, *et al.* Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. *Leukemia* 2008: 1-8.
11. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S *et al.* Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. *J Clin Oncol* 2006; 24(30): 4867-74.

12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. *J Clin Oncol* 1999; 17 (4):1244-53.
13. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. *Ann of Oncology* 2006; 1-6.
14. Reece DE, Hegenbart U, Sanchowala V, Merlini G, Palladini G et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. *Blood* 2011; 118 (4): 865-73.
15. Moreau P, Pylypenko H, Grosicki S, Karamanesht I et.al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncology* 2011; 12: 431-440.
16. Harrouseau JL et al. Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. *J Clin Oncol* 2010; 28:4621-4629.
17. Rosinol L, Oriol A, Teruel AI et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. *Blood* 2012; 120:1589-1596.
18. Sonneveld P, Ingo GH, Schmidt-Wolf B et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial. *J Clin Oncol* 2012; 30(24) :2946-2955.
19. Velcade<sup>®</sup> (bortezomib mannitol boronic ester for injection) Product Monograph, Janssen Inc., Submission Control No. 190153. Date of Revision: March 16, 2016.

## **PART III: CONSUMER INFORMATION**

**Pr BORTEZOMIB FOR INJECTION**  
**Bortezomib (as mannitol boronic ester)**  
 Sterile Powder for Injection  
 3.5 mg bortezomib/vial

**This leaflet is Part III of a three-part “Product Monograph” published when BORTEZOMIB FOR INJECTION was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about BORTEZOMIB FOR INJECTION. Contact your doctor or pharmacist if you have any questions about the drug.**

### **ABOUT THIS MEDICATION**

#### **What the medication is used for:**

BORTEZOMIB FOR INJECTION is used for the treatment of adult patients with:

- Previously untreated Multiple Myeloma (MM) who are unsuitable for stem cell transplantation as part of combination therapy. MM is a cancer of the bone marrow
- Previously untreated MM who are suitable for stem cell transplantation as part of a medically recognized combination therapy for initial treatment prior to stem cell transplant.
- Relapsed MM
- Previously untreated mantle cell lymphoma who are unsuitable for stem cell transplantation. BORTEZOMIB FOR INJECTION will be given as part of a medically recognized combination therapy. Mantle cell lymphoma is a cancer of the blood that affects the white blood cells.
- Relapsed/refractory mantle cell lymphoma.

#### **What it does:**

BORTEZOMIB FOR INJECTION is a chemotherapy medicine, which is medicine used to kill cancer cells.

#### **When it should not be used:**

Do not use BORTEZOMIB FOR INJECTION if you are allergic (hypersensitive) to bortezomib, boron or to any of the other ingredients of BORTEZOMIB FOR INJECTION.

BORTEZOMIB FOR INJECTION must not be given intrathecally.

#### **What the medicinal ingredient is:**

The medicinal ingredient is bortezomib.

#### **What the non-medicinal ingredients are:**

The non-medicinal ingredient is mannitol.

#### **What dosage forms it comes in:**

BORTEZOMIB FOR INJECTION is available as a powder which will be dissolved in a sterile sodium chloride solution before being injected.

Each pack of BORTEZOMIB FOR INJECTION contains one glass vial. Each vial contains 3.5 mg of bortezomib.

The vial stopper is free of natural rubber latex.

### **WARNINGS AND PRECAUTIONS**

#### **Serious Warnings and Precautions**

BORTEZOMIB FOR INJECTION must be administered under the supervision of a physician qualified in the use of anti-cancer drugs.

Overdose ( $\geq 2X$  recommended dose) could result in death.

Serious side effects that may occur with BORTEZOMIB FOR INJECTION include:

- Low blood pressure and other serious heart disorders
- Bleeding into the brain or gastrointestinal tract (stomach or bowel)
- Muscle weakness due to nerve damage (severe motor neuropathy)
- Acute lung disease (acute diffuse infiltrative pulmonary disease)

BEFORE you use BORTEZOMIB FOR INJECTION, talk to your doctor or pharmacist if:

- you have had any bleeding problems, a low level of red blood cells, platelets, or white blood cells, as these conditions may become worse during treatment with BORTEZOMIB FOR INJECTION;
- you are suffering from diarrhea, constipation, nausea or vomiting, as this may become worse during BORTEZOMIB FOR INJECTION treatment;
- you have any problems with your heart or blood pressure including a history of fainting, dizziness or lightheadedness;
- you have any problems with your kidneys;
- you have any problems with your liver;
- you have had any problems in the past with numbness, tingling, or pain in the hands or feet (neuropathy); (This effect may become worse during BORTEZOMIB FOR INJECTION treatment.);
- you have been diagnosed in the past with a condition called amyloidosis (abnormal protein deposition in tissues);

- you have shortness of breath with activity (progressively worsens), cough, and difficulty breathing; (Symptoms may develop or worsen during BORTEZOMIB FOR INJECTION treatment.);
- you are pregnant, planning to become pregnant or breastfeeding.

BORTEZOMIB FOR INJECTION has not been studied in children or adolescents.

#### **Contraception and Pregnancy:**

Both men and women must use effective contraception while receiving BORTEZOMIB FOR INJECTION, and for 3 months after their treatment. You must make sure that you do not become pregnant while receiving BORTEZOMIB FOR INJECTION, but if you do, inform your doctor immediately. BORTEZOMIB FOR INJECTION may cause harm to your unborn baby.

#### **Breast-feeding:**

It is advised that you do not breast-feed while you are receiving BORTEZOMIB FOR INJECTION. If you wish to restart breast-feeding after your BORTEZOMIB FOR INJECTION treatment, you must discuss this with your doctor or nurse, who will tell you when it is safe to do so.

#### **Driving and using machines:**

BORTEZOMIB FOR INJECTION might cause low blood pressure that may lead to tiredness, dizziness, fainting, or blurred vision. Do not drive or operate any dangerous tools or machines if you experience such side effects. Even if you have not felt these effects, you must still be cautious.

### **INTERACTIONS WITH THIS MEDICATION**

Inform your doctor, medical health personnel or pharmacist about all medicines you are taking, whether prescribed for you or bought without a prescription.

If you are a patient on oral antidiabetic medication while receiving BORTEZOMIB FOR INJECTION treatment, check your blood sugar level frequently. Call your doctor if you notice an unusual change.

### **PROPER USE OF THIS MEDICATION**

BORTEZOMIB FOR INJECTION is to be given to you as an injection. BORTEZOMIB FOR INJECTION may be injected:

- into the vein (intravenous injection). The injection will take 3 to 5 seconds, or
- under the skin (subcutaneous injection) of the thigh (right or left) or abdomen (right or left).

The site of injection should be rotated for each following injection. New injections should be at least one inch (2.5 cm) from an old site and never into the areas where the site is tender, bruised, red or hard.

#### **Usual dose:**

The dose will be calculated from your height and weight. The usual dose is 1.3 mg/m<sup>2</sup> body surface area.

#### **Frequency of treatment:**

##### **Previously Untreated Multiple Myeloma**

The treatment consists of nine 6-week treatment cycles. Each treatment cycle consists of 6 weeks. In cycles 1-4, BORTEZOMIB FOR INJECTION is given twice weekly on days 1, 4, 8, 11, 22, 25, 29 and 32. In cycles 5-9, BORTEZOMIB FOR INJECTION is given once a week on days 1, 8, 22 and 29.

##### **Patients Suitable for Stem Cell Transplantation**

If you have not been treated before for multiple myeloma, you will receive BORTEZOMIB FOR INJECTION together with other medicines as initial treatment before you receive high dose chemotherapy and bone marrow transplantation. BORTEZOMIB FOR INJECTION will be given on days 1, 4, 8 and 11, followed by a rest period without treatment. The dose may be adjusted based on how you respond to the treatment.

Your doctor will choose the other chemotherapy medicines for you.

##### **Relapsed Multiple Myeloma and Relapsed/Refractory Mantle Cell Lymphoma**

BORTEZOMIB FOR INJECTION is given twice weekly on days 1, 4, 8 and 11 of a 3- week treatment cycle. In maintenance treatment, BORTEZOMIB FOR INJECTION is given once a week for 4 weeks on days 1, 8, 15 and 22.

Your doctor may change the dosage during the treatment, and will decide the total number of cycles that you need. It all depends on your response to the treatment.

##### **Previously Untreated Mantle Cell Lymphoma**

If you have not been treated before for mantle cell lymphoma you will receive BORTEZOMIB FOR INJECTION together with other chemotherapy agents as prescribed by your doctor.

BORTEZOMIB FOR INJECTION is given on days 1, 4, 8 and 11, followed by a 'rest period' without treatment. The duration of a treatment cycle is 21 days (3 weeks). You might receive up to 8 cycles (24 weeks).

### Overdose:

If you think that you have been given BORTEZOMIB FOR INJECTION more frequently than you should, or too high a dose, or in case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

### Missed dose:

If you think that you have missed a dose of BORTEZOMIB FOR INJECTION, tell your healthcare provider immediately.

## SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, BORTEZOMIB FOR INJECTION can have side effects. The following are the most commonly reported side effects ( $\geq 10\%$ ):

*Blood and lymph disorders:* Low red blood cells, white blood cells or platelets causing anemia, bruising or bleeding

*Eye disorders:* blurred vision

*Gastrointestinal disorders:* feeling sick in the stomach or loss of appetite, diarrhea, constipation, vomiting, abdominal pain, heartburn, stomach ulcers

*General disorders:* general ill feeling, tiredness, or a feeling of weakness, fever, swelling (around the arms, legs or face), shivering

*Infections:* shingles (herpes zoster virus), flu-like symptoms, chest and other infections

*Metabolism and nutrition disorders:* dehydration, losing weight

*Musculoskeletal disorders:* joint or muscle stiffness, muscle cramps, muscle or bone pain, back pain

*Nervous system disorders:* numbness, tingling or burning sensation in the hands or feet, headache, dizziness

*Psychiatric disorders:* difficulty in sleeping, anxiety or depression (feeling down), confusion

*Respiratory disorders:* shortness of breath, cough

*Skin disorders:* rash and/or itching, hives, redness, pain at the injection site when injected under the skin

*Cardiovascular disorders:* sudden fall of blood pressure on standing which may lead to fainting, pericarditis or inflammation of the lining around the heart, increase in blood pressure

The types of side effects that may be experienced are similar whether BORTEZOMIB FOR INJECTION is given by subcutaneous injection or by intravenous injection.

If you notice these or any other effects not mentioned in this leaflet, inform your doctor or pharmacist.

## SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom/effect	Talk with your doctor or pharmacist	
	Only if severe	In all cases
<b>Common</b>		
Fever		√
Chest and other infections including shingles		√
Diarrhea	√	
Vomiting	√	
Dehydration (dry mouth, excessive thirst, dark yellow urine)		√
Nausea	√	
Difficulty breathing/breathlessness	√	
Altered sensation/pins and needles in hands or feet	√	
Pain and altered sensation		√
Bleeding from gums or other sites or abnormal bruising		√
Tiredness/lethargy	√	
Joint pain and muscle cramps	√	
Headache	√	
Low blood pressure (dizziness or fainting)		√
Increase in blood pressure		√
<b>Uncommon</b>		
Swelling of the face or neck		√
Swelling of the ankles	√	
Chest palpitations/awareness of abnormal heart rhythm/abnormal electrical signal from an electrocardiogram (ECG) reading		√
Angina (chest pain)	√	
Loss of appetite	√	
Severe abdominal pain with		√



**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

Symptom/effect	Talk with your doctor or pharmacist	
	Only if severe	In all cases
or without bleeding		
Constipation	✓	
Yellowing of skin or whites of eyes		✓
Skin rash		✓
Difficulty moving limbs, walking or speaking, stroke		✓
Confusion		✓
Seizure (fits)		✓
Loss of control or inability to pass urine		✓
Muscle weakness	✓	
New onset or worsening neurological signs or symptoms such as confusion or problems thinking, loss of balance, blurred vision or loss of vision, decreased strength or weakness in an arm or leg or change in the way of walking or talking (these may be signs of a serious brain infections and your doctor may suggest further testing and follow-up).		✓
Anaphylactic (allergic) reaction		✓

Two cases of sudden death have been reported in clinical trials with bortezomib.

*This is not a complete list of side effects. For any unexpected effects while taking BORTEZOMIB FOR INJECTION, contact your doctor or pharmacist.*

**HOW TO STORE IT**

BORTEZOMIB FOR INJECTION should be kept out of the reach of children.

BORTEZOMIB FOR INJECTION should be stored as follows:

**Powder for injection:**

It should be stored between 15°C - 30°C. Keep the container in the outer carton in order to protect it from light. Do not use after the expiry date stated on the vial and the carton.

**Reconstituted solution:**

The reconstituted solution could be administered within eight hours of preparation when stored in the original vial or in a syringe between 15°C to 30°C. The total storage time for the reconstituted material must not exceed eight hours when exposed to normal indoor lighting.

**Reporting Side Effects**

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

**3 ways to report:**

- Online at MedEffet (<http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php>);
  - By calling 1-866-234-2345 (toll-free);
  - By completing a Patient Side Effect Reporting Form and sending it by:
    - Fax to 1-866-678-6789 (toll-free), or
    - Mail to: Canada Vigilance Program  
Health Canada, Postal Locator  
0701E Ottawa, ON  
K1A 0K9
- Postage paid labels and the Patient Side Effect Reporting Form are available at MedEffet (<http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php>).

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical*

**MORE INFORMATION**

This document plus the full product monograph, prepared for health professionals can be found by contacting Teva Canada Limited at:  
1-800-268-4127 ext. 1255005 (**English Canada**)  
or 1-877-777-9117 (**French Canada**)  
or [druginfo@tevacanada.com](mailto:druginfo@tevacanada.com)

This leaflet was prepared by:

Teva Canada Limited  
30 Novopharm Court  
Toronto, Ontario  
Canada, M1B 2K9  
[www.tevacanada.com](http://www.tevacanada.com)

Last revised: May 26, 2016